

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/85177 A1

(51) International Patent Classification⁷: **A61K 31/70,**
48/00, C07H 21/04, C12N 9/10 [JP/US]; 7405 Charmant Drive #2206, San Diego, CA 92122 (US).

(21) International Application Number: PCT/US01/15452

(74) Agents: GASHLER, Andrea, L. et al.; Campbell & Flores LLP, 7th floor, 4370 La Jolla Village Drive, San Diego, CA 92122 (US).

(22) International Filing Date: 10 May 2001 (10.05.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/569,320 11 May 2000 (11.05.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CII, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/569,320 (CIP)
Filed on 11 May 2000 (11.05.2000)

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for all designated States except US): THE BURNHAM INSTITUTE [US/US]; 10901 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): FUKUDA, Minoru [US/US]; 2818 Passy Avenue, San Diego, CA 92122 (US). YEH, Juiun-Chern [—US]; 3128 Via Alicante Drive #E, La Jolla, CA 92037 (US). HIRAKAWA, Nobuyoshi



WO 01/85177 A1

(54) Title: THE MECA-79 ANTIGEN AND RELATED METHODS

(57) Abstract: The present invention provides the structure of the MECA-79 antigen and methods of treating L-selectin-mediated conditions by modulating enzymes that are required for formation of this antigen.

**IDENTIFICATION OF THE MECA-79 ANTIGEN AND RELATED
METHODS OF TREATING L-SELECTIN-MEDIATED CONDITIONS**

This application was made with government support under CA 71932, CA 48737 and CA 33000 awarded by 5 the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

10 This invention relates generally to lymphocyte homing and pathologies involving chronic or acute inflammation mediated by L-selectin and, more specifically, to identification of the L-selectin ligand antigen, MECA-79.

15 **BACKGROUND INFORMATION**

In mammals, lymphocytes circulate in the vascular and lymphatic compartments, allowing maximum exposure of lymphocytes to foreign pathogens.

18 Lymphocytes leave the vascular compartment at lymph nodes, traverse the lymphatic organs, and then return to the vascular system. This directed flow of lymphocytes is dependent on carbohydrate ligands present on specialized endothelial cells, known as high endothelial venules (HEV; Arbones et al., Immunity 1:247-260 (1994)).
25 Although the structure of these carbohydrate ligands is unknown, lymphocyte binding to HEV depends on sialic acid on HEV and can be inhibited by fucosylated sulfated oligosaccharides (Rosen and Bertozzi, Curr. Biol.

261:261-264 (1996)). The homing receptor on lymphocytes is L-selectin, which contains an amino-terminal carbohydrate-binding domain similar to that of the hepatic lectin. Carbohydrate-binding activity of these 5 lectins is calcium-dependent, and they are therefore termed "C-type" lectins (Drickamer, "Molecular Structure of Animal Lectins" in Fukuda and Hindsgaul (Eds), Molecular Glycobiology Oxford University Press: Oxford, U.K. (1994)). Counterreceptors (ligands) on HEV capture 10 circulating lymphocytes via L-selectin-dependent adhesion, leading to transmigration. It has been shown that L-selectin is required for this process (Arbones et al., *supra*, 1994).

The HEV-expressed counterreceptors (ligands) 15 for L-selectin have thus far eluded molecular identification. Consistent with the presence of a C-type lectin domain at the amino terminus of L-selectin, all of the ligands identified to date contain carbohydrate-based recognition determinants. In mouse lymph nodes, two such 20 ligands have been identified as GlyCAM-1 and CD34, both of which are sialomucins (Lasky et al., Cell 69:927-938 (1992); Baumhueter et al., Science 262:436-438 (1993)). CD34 is a type I transmembrane glycoprotein, whereas GlyCAM-1 is a secreted molecule that lacks a 25 transmembrane domain. Additionally, MadCAM-1, which contains a mucin domain in addition to Ig-like domains, can function as a ligand for L-selectin in Peyer's patches (Berg et al., Nature 366:695-698 (1993); and Bargatze et al., Immunity 3:99-108 (1995)). Four human 30 glycoprotein ligands have been biochemically identified, and two of these have been cloned as CD34 and podocalyxin (Berg et al., J. Cell Biol. 114:343-349 (1991); Puri et

al., J. Cell Biol. 131:261-270 (1995); and Sasetti et al., J. Exp. Med. 187:1965-1975 (1998)). All of the human and murine ligands are sialomucin-like, (Puri et al., *supra*, 1995), and CD34 and podocalyxin have a similar overall domain structure (Figure 1) with significant sequence homology in their cytoplasmic domains (Sasetti et al., *supra*, 1998). Notably, only certain glycoforms react with L-selectin. For example, naturally occurring forms of GlyCAM-1, MadCAM-1, CD34 and podocalyxin exist which fail to bind L-selectin due to the absence of necessary post-translational modification (Berg et al., Nature 366:695-698 (1993); Puri et al., *supra*, 1995; Sasetti et al., *supra*, 1998; and Dowbenko et al., J. Clin. Invest. 92:952-960 (1993)). Thus, although CD34 and podocalyxin are widely distributed on vascular endothelium, a limited number of vessels (including HEV) express L-selectin-reactive glycoforms (Sasetti et al., *supra*, 1998; and Baumhueter et al., Blood 84:2554-2565 (1994)).

GlyCAM-1 and CD34 were originally identified as L-selectin ligands in extracts of mouse lymph nodes using a recombinant L-selectin/IgG chimera (Lasky et al., *supra*, 1992; Baumhueter et al., *supra*, 1993; and Imai et al., J. Cell Biol. 113:1213-1221 (1991)). Furthermore, a monoclonal antibody, MECA-79, stains HEV in mouse lymph nodes and blocks both lymphocyte attachment to HEV *in vitro* and short-term homing of lymphocytes to lymph nodes *in vivo* (Streeter et al., Nature 331:41-43 (1988)). The MECA-79 monoclonal is remarkable in that it reacts with HEV across a wide range of species including mouse and human (Girard et al., FASEB J. 12:603-612 (1998)). Significantly, MECA-79 and L-selectin/IgG stain the same

- complex of glycoproteins in mouse and human lymphoid organs (Sassetti et al., *supra*, 1998; and Hemmerich et al., J. Exp. Med. 180:2219-2226 (1994)). This complex of four or more glycoproteins defined by reactivity with
- 5 MECA-79 is known as peripheral lymph node addressin (PNAd). Although the structure of the MECA-79 antigen has eluded identification, the epitope is believed to be sulfated (Hemmerich et al., *supra*, 1994) and, in particular, to include a GlcNAc-6-sulfate modification
- 10 (Kimura et al., Proc. Natl. Acad. Sci. 96:4530-4535 (1999)). Furthermore, previous characterization indicates that the MECA-79 epitope is independent of sialylation and fucosylation (Hemmerich et al., *supra*, 1994; and Maly et al., Cell 86:643-653 (1996)).
- 15 Nevertheless, the physiologically relevant sulfated structures necessary for L-selectin ligand activity remain to be identified.

- L-selectin and its ligands are implicated in lymphocyte recruitment in a variety of chronic inflammatory diseases, and L-selectin ligand activity including MECA-79 expression is induced on microvascular venular endothelium in rheumatoid arthritis, lymphocytic thyroiditis, and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis (Michie et al.,
20 Am. J. Pathol. 143:1688-1698 (1993); and Salmi et al.,
25 Gastroenterology 106:596-605 (1994)). Increased MECA-79 expression also is associated with nonobese diabetes in the mouse and with transplant rejection (Hanninen et al.,
J. Clin. Invest. 92:2509-2515 (1993); and Toppila et al.,
30 Am. J. Pathol. 155:1303-1310 (1999)).

Methods of controlling L-selectin activity would be desirable in order to reduce inflammatory responses mediated by L-selectin. Such methods could be used to treat or prevent conditions such as acute or chronic inflammation; allograft rejection; or tumor metastasis. However, methods of specifically controlling L-selectin activity await elucidation of the sulfated carbohydrate structure on L-selectin ligands, and identification of the enzymes that manufacture the L-selectin ligand carbohydrate determinants.

Thus, there is a need for identification of the L-selectin ligand carbohydrate structure and identification of the enzyme or enzymes that produce this structure. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The present invention provides a method of modifying an acceptor molecule by contacting the acceptor molecule with an isolated β 1,3GnT, or an active fragment thereof, under conditions that allow addition of core 1 GlcNAc linkages to the acceptor molecule, where the β 1,3GnT or active fragment thereof directs expression of a MECA-79 antigen. A β 1,3GnT useful for modifying an acceptor molecule according to a method of the invention can have, for example, substantially the amino acid sequence of human β 1,3GnT (SEQ ID NO: 2) or substantially the amino acid sequence of murine β 1,3GnT (SEQ ID NO: 4).

The invention also provides a method of treating or preventing an L-selectin-mediated condition

in a subject by reducing the expression or activity of a $\beta 1,3GnT$ that directs expression of a MECA-79 antigen. In a method of the invention, the expression or activity of a $\beta 1,3GnT$ can be reduced, for example, by administering 5 to a subject an oligosaccharide L-selectin antagonist that inhibits the binding of L-selectin to a MECA-79 antigen. Such an L-selectin antagonist can contain, for example, the oligosaccharide $Gal\beta 1 \rightarrow 4(SO_3 \rightarrow 6) GlcNAc\beta 1 \rightarrow 3Gal\beta 1 \rightarrow 3GalNAc$ or the oligosaccharide 10 $NeuNAc\alpha 2 \rightarrow 3Gal\beta 1 \rightarrow 4[sulfo \rightarrow 6(Fuc\alpha 1 \rightarrow 3)GlcNAc]$ $\beta 1 \rightarrow 3Gal\beta 1 \rightarrow 3GalNAc\alpha 1$, or, in another embodiment, multimers of one or both of these oligosaccharides. In a further embodiment, an L-selectin-mediated condition is treated or prevented by administering to the subject inhibitory 15 antibody material that specifically binds $\beta 1,3GnT$. In yet a further embodiment, an L-selectin-mediated condition is treated or prevented by administering to the subject a $\beta 1,3GnT$ antisense nucleic acid molecule that has, for example, at least 20 nucleotides complementary 20 to SEQ ID NO: 1 or SEQ ID NO: 3. In another embodiment, a method of the invention is practiced by reducing the expression or activity of a $\beta 1,3GnT$ that directs expression of a MECA-79 antigen in combination with reducing the expression or activity of L-selectin 25 sulfotransferase-2 (LSST-2) in the subject.

The present invention also provides an isolated L-selectin antagonist containing an extended core 1 structure which includes the oligosaccharide $Gal\beta 1 \rightarrow 4(SO_3 \rightarrow 6) GlcNAc\beta 1 \rightarrow 3Gal\beta 1 \rightarrow 3GalNAc$. In a further 30 embodiment, the invention provides an isolated L-selectin antagonist containing the oligosaccharide $NeuNAc\alpha 2 \rightarrow 3Gal\beta 1 \rightarrow 4[sulfo \rightarrow 6(Fuc\alpha 1 \rightarrow 3)GlcNAc]\beta 1 \rightarrow 3Gal\beta 1 \rightarrow 3GalNA$

col. In yet another embodiment, an isolated L-selectin antagonist of the invention contains multimers of one or both the the oligosaccharides
Gal β 1 \rightarrow 4 (SO₃ \rightarrow 6) GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc or
5 Gal β 1 \rightarrow 4 (SO₃ \rightarrow 6) GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc.

The present invention also provides an isolated polypeptide which contains an amino acid sequence encoding a L-selectin sulfotransferase-2 (LSST-2), or an active fragment thereof, that directs expression of a
10 MECA-79 antigen in Chinese hamster ovary (CHO) cells. An isolated polypeptide of the invention can have, for example, substantially the amino acid sequence of human LSST-2 (SEQ ID NO: 6).

15 The present invention further provides substantially purified antibody material that specifically binds a LSST-2 that directs expression of a MECA-79 antigen in CHO cells. Such antibody material, which can be polyclonal or monoclonal antibody material,
20 specifically binds, for example, human LSST-2 having the amino acid sequence SEQ ID NO: 6.

The present invention further provides an isolated nucleic acid molecule which contains a nucleic acid sequence encoding a LSST-2 or an active fragment
25 thereof that directs expression of a MECA-79 antigen in CHO cells. An isolated nucleic acid molecule of the invention can encode, for example, a LSST-2 that has substantially the amino acid sequence of human LSST-2 (SEQ ID NO: 6) and can be, for example, SEQ ID NO: 5.
30 The invention further provides vectors and related host cells that contain a nucleic acid molecule encoding a

LSST-2 or active fragment thereof that directs expression of a MECA-79 antigen in CHO cells. In one embodiment, such a vector is a mammalian expression vector.

The invention also provides an isolated
5 antisense nucleic acid molecule which contains a nucleotide sequence that specifically binds to SEQ ID NO: 5, shown in Figure 4. Such an isolated antisense nucleic acid molecule can have, for example, at least 20 nucleotides complementary to SEQ ID NO: 5. In one
10 embodiment, an isolated antisense nucleic acid molecule contains a nucleotide sequence complementary to the sequence ATG.

Also provided herein is an oligonucleotide, which contains a nucleotide sequence having at least 10
15 contiguous nucleotides of SEQ ID NO: 5, or a nucleotide sequence complementary thereto. An oligonucleotide of the invention can have, for example, at least 15 contiguous nucleotides of SEQ ID NO: 5, or a nucleotide sequence complementary thereto.

20 The present invention also provides a method of modifying an acceptor molecule by contacting the acceptor molecule with an isolated LSST-2, or an active fragment thereof, under conditions that allow addition of a sulfate to a GlcNAc acceptor molecule, where the LSST-2
25 or active fragment thereof directs expression of a MECA-79 antigen in CHO cells. A LSST-2 useful for modifying an acceptor molecule according to a method of the invention can have, for example, substantially the amino acid sequence of human LSST-2 (SEQ ID NO: 6) or an
30 active fragment thereof.

The invention also provides a method of treating or preventing an L-selectin-mediated condition in a subject by reducing the expression or activity of a LSST-2 that directs expression of a MECA-79 antigen in 5 CHO cells. In one embodiment, an L-selectin-mediated condition is treated or prevented by administering to the subject inhibitory antibody material that specifically binds LSST-2. In another embodiment, an L-selectin-mediated condition is treated or prevented by 10 administering to the subject a LSST-2 antisense nucleic acid molecule that has, for example, at least 20 nucleotides complementary to SEQ ID NO: 5.

The invention also provides an isolated polypeptide that contains an amino acid sequence encoding 15 substantially the amino acid sequence of intestinal GlcNAc 6-sulfotransferase (I-GlcNAc6ST) or an active fragment thereof. Such a polypeptide of the invention can have, for example, substantially the amino acid sequence of SEQ ID NO: 8.

20 In addition, the invention also provides substantially purified antibody material that specifically binds an isolated polypeptide having an amino acid sequence encoding substantially the amino acid sequence of I-GlcNAc6ST or an active fragment thereof. Such antibody material, which can be polyclonal or monoclonal antibody material, specifically binds, for example, I-GlcNAc6ST having the amino acid sequence SEQ ID NO: 8.

30 The present invention further provides an isolated nucleic acid molecule which contains a nucleic

10

acid sequence encoding an I-GlcNAc6ST or an active fragment thereof. An isolated nucleic acid molecule of the invention can encode, for example, an I-GlcNAc6ST having substantially the amino acid sequence of murine 5 I-GlcNAc6ST (SEQ ID NO: 8) and can be, for example, SEQ ID NO: 7. The invention further provides vectors and related host cells that contain a nucleic acid molecule encoding an I-GlcNAc6ST or active fragment thereof. In one embodiment, such a vector is a mammalian expression 10 vector.

The invention also provides an isolated antisense nucleic acid molecule which contains a nucleotide sequence that specifically binds to SEQ ID NO: 7, shown in Figure 10. Such an isolated antisense 15 nucleic acid molecule can have, for example, at least 20 nucleotides complementary to SEQ ID NO: 7. In one embodiment, an isolated antisense nucleic acid molecule contains a nucleotide sequence complementary to the sequence ATG.

20 Also provided herein is an oligonucleotide, which contains a nucleotide sequence having at least 10 contiguous nucleotides of SEQ ID NO: 7, or a nucleotide sequence complementary thereto. An oligonucleotide of the invention can have, for example, at least 15 25 contiguous nucleotides of SEQ ID NO: 7, or a nucleotide sequence complementary thereto.

The present invention also provides a method of modifying an acceptor molecule by contacting the acceptor molecule with an isolated I-GlcNAc6ST, or an active

fragment thereof, under conditions that allow addition of a sulfate to a GlcNAc acceptor molecule.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a model of lymph node HEV ligands for L-selectin. Four sialomucins recognized by MECA-79 are shown. GlyCAM-1, CD34, and Sgp200 have been identified in mouse lymph node. CD34, podocalyxin and Sgp200 have been identified in human tonsils. The complex, defined by purification with MECA-79, is denoted the peripheral lymph node addressin (PNAd). The cDNA encoding Sgp200 (sulfated glycoprotein of 200 kd) has yet to be cloned. White circles designate posttranslational modifications including sialylation, fucosylation, and sulfation. CD34 and podocalyxin share the same overall structural organization, each having an amino-terminal mucin domain, a presumed globular domain with cysteines, a transmembrane domain, and homologous cytoplasmic tails.

Figure 2 shows the human β 1,3GnT nucleotide sequence (SEQ ID NO: 1) and predicted amino acid sequence (SEQ ID NO: 2).

Figure 3 shows the murine β 1,3GnT nucleotide sequence (SEQ ID NO: 3) and predicted amino acid sequence (SEQ ID NO: 4).

Figure 4 shows the human L-selectin sulfotransferase-2 (hLSST-2) nucleotide sequence (SEQ ID NO: 5) and predicted amino acid sequence (SEQ ID NO: 6).

Figure 5 shows a CLUSTALW alignment of mouse β3GalT-I, -II, -III and -IV and mouse β3GnT proteins. Conserved residues are shaded. White arrows mark the positions of the cysteine residues conserved among β3GalT 5 proteins. The black arrow shows the position of the cysteines conserved in the five proteins.

Figure 6 shows *in vitro* substrate specificity of human β1,3GnT.

Figure 7 shows MECA-79 staining of transfected 10 CHO/CD34 cells.

Figure 8 shows the results of a rolling experiment performed with four stably transfected CHO cell lines. Open circles represent the CHO/CD34/FT7/hLSST-2 cell line. Open squares represent 15 the CHO/CD34/FT7/hLSST-2/C2GnT-L cell line. Filled squares represent the CHO/CD34/FT7/hLSST-2/core 1 extension β1,3GnT cell line. Filled circles represent the CHO/CD34/FT7/hLSST-2/C2GnT-L/core 1 extension β1,3GnT line cell.

20 Figure 9 shows inhibition of anti-MECA-79 antibody binding to MECA-79-reactive CD34 chimeric proteins by synthetic oligosaccharides including sialylated and sialylated, fucosylated forms of the extended core 1 structure.

25 Figure 10 shows the murine intestinal-GlcNAC 6-sulfotransferase (I-GlcNAc6ST) nucleotide sequence (SEQ ID NO: 7) and predicted amino acid sequence (SEQ ID NO: 8).

DETAILED DESCRIPTION OF THE INVENTION

Lymphocyte homing is important for the surveillance of foreign pathogens. Extravasation of lymphocytes in peripheral lymph nodes is mediated through 5 L-selectin binding to L-selectin ligands, sulfated sialyl Lewis^x present on high endothelial venules (HEV). Recently cloned L-selectin ligand sulfotransferases (LSST or HEC-GlcNAc6ST) form core 2-based selectin ligand functional in rolling assays (Hiraoka et al., Immunity 10 11:79-89 (1999), and Bistrup et al., J. Cell. Biol. 145:899-910 (1999)). The expression of LSST is highly restricted to HEV, while the sulfotransferase GlcNAc6ST is more widely present and less specific in acceptor substrate requirement.

15 Analysis of core 2 GnT-leukocyte type knockout mice has indicated that lymphocyte homing and expression of MECA-79 antigen persist even after the gene for the leukocyte type core 2 GnT has been inactivated (Ellies et al., Immunity 9:881-890 (1998)). Structural analysis of 20 L-selectin ligands in HEV of the knockout mice demonstrated that the major oligosaccharides remaining are based on extended core 1 structure such as NeuNAc α 2-3Gal β 1-4[sulfo-6(Fuc α 1-3)GlcNAc] β 1-3Gal β 1-3GalNAc α 1-R. As disclosed herein, a novel 25 β 1,3-N-acetylglucosaminyl-transferase has been isolated that extends core 1 and forms GlcNAc β 1-3Gal β 1-3GalNAc α 1-R. As further disclosed herein, human L-selectin sulfotransferase-2 (hLSST-2), is unique in the ability to produce, when co-transfected 30 into CHO cells together with β 1,3-GnT, NeuNAc α 2-3Gal β 1-4[sulfo-6(Fuc α 1-3)GlcNAc]

- $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc $\alpha 1\rightarrow R$, resulting in expression of the MECA-79 epitope. As further disclosed herein, oligosaccharides produced in CHO cells expressing both human $\beta 1,3$ GnT and human LSST-2 support
- 5 L-selectin-mediated lymphocyte rolling (see Example III). These results demonstrate that 6-sulfo sialyl Lewis X structures on core 1 or core 2 oligosaccharides can serve as L-selectin ligands on high endothelial venules.

As further disclosed herein in Example IV,

10 several synthetic oligosaccharides were compared for the ability to inhibit binding of anti-MECA-79 antibody to the MECA-79 antigen produced in the media of CHO/CD34/FT7/hLSST-2/core 1 $\beta 1,3$ GnT cells. As shown in Figure 9, only the synthetic oligosaccharide with the

15 6-S-extended core 1 structure (Gal $\beta 1\rightarrow 4$ (SO₃ \rightarrow 6) GlcNAc $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc) was able to inhibit antibody binding to MECA-79, defining Gal $\beta 1\rightarrow 4$ (SO₃ \rightarrow 6) GlcNAc $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc as a minimal MECA-79 epitope. Sialylated or sialylated and fucosylated forms of the

20 6-sulfo extended core 1 structure (NeuNAc $\alpha 2\rightarrow 3$ Gal $\beta 1\rightarrow 4$ [Fuc $\alpha 1\rightarrow 3$ (sulfo \rightarrow 6)]GlcNAc $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalN Ac $\alpha 1\rightarrow$ octyl) also were efficient inhibitors of antibody binding (Figure 9). As further disclosed herein, the 6-sulfo group was absolutely required, since

25 non-sulfated, extended core 1 did not inhibit MECA-79 antibody binding (Figure 9). In addition, the terminal galactose residue in the N-acetyllactosaminyl core 1 was part of the epitope, since the agalacto form required more than a 10 fold greater concentration to achieve

30 equivalent inhibition (Figure 9). An absolute requirement for core 1 structure was also demonstrated, since sulfated N-acetyllactosamine lacking a core 1

structure did not show detectable inhibition (Figure 9). These results indicate that the minimum epitope of MECA-79 is the sulfated, extended core1 structure Gal β 1 \rightarrow 4(sulfo \rightarrow 6)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc α 1 \rightarrow R, and that the 5 sialylated and sialylated, fucosylated forms (6-sulfo sLe \times in extended core 1) retain MECA-79 reactivity.

Thus, the present invention is directed to the long-awaited discovery of the structure and minimum epitope of the L-selectin ligand, MECA-79, and to 10 identification of a β 1,3-N-acetylglicosaminyl transferase (β 1,3GnT) and a human sulfotransferase (hLSST-2) that can produce this ligand when co-expressed in CHO cells. These discoveries provide a basis for diagnosing and 15 treating L-selectin-mediated conditions, including acute and chronic inflammation, transplant rejection and tumor metastasis.

The present invention relates to an isolated polypeptide which contains an amino acid sequence encoding a β 1,3GnT, or an active fragment thereof, that 20 directs expression of a MECA-79 antigen in CHO cells. Such an isolated polypeptide can have, for example, substantially the amino acid sequence of human β 1,3GnT (SEQ ID NO: 2) or substantially the amino acid sequence of murine β 1,3GnT (SEQ ID NO: 4).

25 The term " β 1,3-N-acetylglicosaminyl-transferase," as used herein, is synonymous with " β 1,3GnT" and means an enzyme that catalyzes the β 1 \rightarrow 3 linkage of a N-acetylglicosamine (GlcNAc) residue to an acceptor molecule. A β 1,3GnT useful in the invention is 30 a core 1 extension enzyme and, therefore, catalyzes the

$\beta 1 \rightarrow 3$ linkage of a GlcNAc residue to the core 1 structure Gal $\beta 1 \rightarrow 3$ GalNAc α -R.

A $\beta 1,3$ GnT that directs expression of a MECA-79 epitope can have, for example, substantially the amino acid sequence of the human $\beta 1,3$ GnT shown in Figure 2 as SEQ ID NO: 2 or substantially the amino acid sequence of the murine $\beta 1,3$ GnT shown in Figure 3 as SEQ ID NO: 4. Human $\beta 1,3$ GnT polypeptide (SEQ ID NO: 2) is a type II membrane protein of 352 amino acids. Human $\beta 1,3$ GnT (SEQ ID NO: 2) shares 66.5% amino acid identity with murine $\beta 1,3$ GnT (SEQ ID NO: 4). Regions highly conserved between human and murine $\beta 1,3$ GnT are present, for example, at amino acids 158 to 245, 263 to 322 and 330 to 361 of SEQ ID NO: 2. As disclosed in Example IB, human $\beta 1,3$ GnT (SEQ ID NO: 2) forms the MECA-79 antigen when expressed with L-selectin ligand sulfotransferase-2 in Chinese hamster ovary (CHO) cells. Thus, such a $\beta 1,3$ GnT is characterized, in part, by the ability to direct expression of a MECA-79 antigen.

The mouse monoclonal antibody, MECA-79, stains HEV in mouse lymph nodes and blocks lymphocyte attachment to HEV *in vitro* as well as short-term homing of lymphocytes to lymph nodes *in vivo* (Streeter et al., 25 *supra*, 1988). Furthermore, the MECA-79 monoclonal antibody reacts with HEV across a variety of species and stains the same complex of glycoproteins in mouse and human lymphoid organs (Girard et al., *supra*, 1998; Sasetti et al., *supra*, 1998; Hemmerich et al. *supra*, 30 1994). Thus, while the carbohydrate-based recognition determinants on the HEV-expressed L-selectin ligands CD34, podocalyxin, Sgp200 and GlyCAM-2 remain unknown,

these L-selectin ligands contain the MECA-79 antigen (Hemmerich, *supra*, 1994).

As used herein, the term "MECA-79 antigen" means a carbohydrate-containing epitope that specifically reacts with the MECA-79 monoclonal antibody described in Hemmerich, *supra*, 1994. An exemplary MECA-79 antigen is provided herein as $\text{Gal}\beta 1\rightarrow 4(\text{SO}_3\rightarrow 6)\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 3\text{GalNAc}$. The phrase "directs expression of a MECA-79 antigen" refers to production of a carbohydrate-containing epitope that specifically reacts with the MECA-79 monoclonal antibody. It is understood that an enzyme "directs expression of a MECA-79 antigen" only under the appropriate conditions. Such conditions include availability of a core 1 acceptor molecule and an appropriate donor molecule and further include the presence of one or more additional enzymes. Human $\beta 1,3\text{GnT}$ together with the human sulfotransferase LSST-2, but not other sulfotransferases, directs expression of the MECA-79 antigen in CHO cells.

The invention provides a method of treating or preventing an L-selectin-mediated condition in a subject by reducing the expression or activity of a $\beta 1,3\text{GnT}$ that directs expression of a MECA-79 antigen. If desired, a method of the invention can be practiced by reducing the expression or activity of a $\beta 1,3\text{GnT}$ that directs expression of a MECA-79 antigen in combination with reducing the expression or activity of L-selectin sulfotransferase-2 (LSST-2) in the subject.

As used herein, the term "L-selectin-mediated condition" means any pathology or disorder involving the

L-selectin ligand, MECA-79. Such an L-selectin-mediated condition generally can be, for example, acute or chronic inflammation, allograft rejection, or tumor metastasis. An L-selectin-mediated condition also can be, for 5 example, organ transplant rejection, which is typically accompanied by an influx of lymphocytes into the graft. For example, in a rat model of acute cardiac allograft rejection, Toppila et al. demonstrated the induction of L-selectin ligands including MECA-7 on flat-walled 10 venules and capillaries within rejecting cardiac allograft (Toppila et al., Am. J. Pathol. 155:1303-1310 (1999)). Toppila et al. further observed a correlation between the staining intensity of L-selectin ligands on vessels and the severity of acute rejection of heart 15 allografts in humans. L-selectin-mediated conditions further can include rheumatoid arthritis; inflammatory bowel diseases such as Crohn's disease and ulcerative colitis; inflammatory disorders of the skin such as allergic contact dermatitis, psoriasis and Lichen planus; 20 lymphomas; chronic pneumonia; delayed-type hypersensitivity reactions; diabetes; and hyperplastic thymus, each of which are characterized by expression of MECA-79 in HEV-like vessels (Rosen, Am. J. Pathol. 155:1013-1020 (1999); see, also, Table 1). It is 25 understood that these and other conditions of acute or chronic inflammation, allograft rejection or tumor metastasis can be an "L-selectin-mediated" condition that can be treated according to a method of the invention.

Table 1

L-selectin-mediated conditions

Organ	Disease process	Reference
Synovium	Rheumatoid arthritis	Michie et al., <u>Am. J. Path.</u> 143:1688-1698 (1993); Van Dinther-Jansses et al., <u>J. Rheum.</u> 17:11-17 (1990)
Gut	Crohn's disease	Salmi et al., <u>Gastroenterology</u> 106:596-605 (1994); Duijvestijn et al., <u>J. Immunol.</u> 138:713-719 (1987)
Gut	Ulcerative colitis	Salmi et al., <u>Eur. J. Immunol.</u> 22:835-843 (1992)
Skin	Cutaneous sites of inflammation such as allergic contact dermatitis, psoriasis and lichen planus	Michie et al., <i>supra</i> , 1993; Arvilommi et al., <u>Eur. J. Immunol.</u> 26:825-833 (1996)
Skin	Cutaneous lymphomas	Michie et al., <i>supra</i> , 1993
Lung	Chronic interstitial pneumonia	
Skin	Delayed-type hypersensitivity reaction	Mackay et al., <u>Eur. J. Immunol.</u> 22:835-843 (1992)
Pancreas	Diabetes	Hanninen et al., <u>J. Clin. Invest.</u> 92:2509-2515 (1993)
Thymus	Hyperplastic thymus	Michie et al., <u>Am. J. Path.</u> 147:412-421 (1995)

The term "reducing the expression or activity" as used herein to a $\beta 1,3GnT$, means that the amount of functional $\beta 1,3GnT$ polypeptide or activity is diminished

in the subject in comparison with the amount of functional β 1,3GnT polypeptide in an untreated subject. Similarly, when used in reference to LSST-2 expression or activity, the term "reduced" means that the amount of 5 functional LSST-2 polypeptide or activity is reduced in the treated subject as compared to an untreated subject. Thus, the term "reduced," as used herein, encompasses the absence of a β 1,3GnT that directs expression of a MECA-79 antigen or a LSST-2, as well as protein expression that 10 is present but reduced as compared to the level of β 1,3GnT or LSST-2 expression in an untreated subject. Furthermore, the term reduced refers to suppressed refers to β 1,3GnT or LSST-2 protein expression that is diminished throughout the entire domain of β 1,3GnT or 15 LSST-2 expression, or to expression that is reduced in some part of the β 1,3GnT or LSST-2 expression domain, provided that expression of the MECA-79 antigen is decreased.

As used herein, the term "reduced" also 20 encompasses an amount of β 1,3GnT or LSST-2 polypeptide that is equivalent to wild type β 1,3GnT or LSST-2 expression, but where the β 1,3GnT or LSST-2 polypeptide has a reduced level of activity. For example, mutations within the catalytic domain of β 1,3GnT or LSST-2 that 25 reduce glucosaminyltransferase activity or sulfotransferase activity, respectively, are encompassed within the meaning of the term "reduced."

The present invention relates, in part, to the use of carbohydrate-based drugs for treatment of an 30 L-selectin-mediated condition such as rheumatoid arthritis, inflammatory bowel disease or diabetes.

Carbohydrate drugs are well known in the art and include, for example, Acarbose, a maltotetraose analog for treatment of diabetes, which acts as a competitive inhibitor of sucrase and α -amylase (Bayer AG; Balfour and 5 McTavish, Drugs 46:1025 (1993)). Other carbohydrate drugs include RelenzaTM (GG-167, zanamivir), a sialic acid analog for treatment of influenza which is a selective inhibitor of viral neuramidases (Glaxo Wellcome/Biot; Hayden et al., JAMA 275:295 (1996)), and SYNSORB PkTM, an 10 oligosaccharide conjugate for treatment of *E. coli* O157:H7 infection developed by SYNSORB Biotech. Additional carbohydrate-based drugs are well known in the art (see, for example, Dumitru (Ed.), Polysaccharides in Medicinal Applications Dekker, New York (1996)).

15

In one embodiment, the invention provides a method of treating or preventing an L-selectin-mediated condition in a subject by administering to the subject an oligosaccharide L-selectin antagonist that inhibits the 20 binding of L-selectin to a MECA-79 antigen. Such an L-selectin antagonist can contain, for example, the oligosaccharide Gal β 1 \rightarrow 4(SO₃ \rightarrow 6)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc or the oligosaccharide NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 4[sulfo \rightarrow 6(Fuc α 1 \rightarrow 3)GlcNAc] β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc α 1 or, in another embodiment, 25 multimers of one or both of these oligosaccharides.

As disclosed herein, the MECA-79 epitope has the structure Gal β 1 \rightarrow 4(SO₃ \rightarrow 6)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc and is based on a core 1 structure. As further disclosed herein, an L-selectin ligand contains the MECA-79 related 30 structure NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 4[sulfo \rightarrow 6(Fuc α 1 \rightarrow 3)GlcNAc] β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc α 1. The term "core 1," as used herein, means the core structure Gal β 1 \rightarrow 3GalNAc \rightarrow R. In conformance

with accepted carbohydrate and chemical nomenclature, "Gal" means galactose; "GalNAc" means N-acetylgalactosamine; "GlcNAc" means N-acetylglucosamine; "SO₃" means sulfate; and "NeuNAc" means N-acetylneuraminate, also known as sialic acid. "R" can be a serine or threonine residue of a peptide or protein or, for example, an octyl, O-methyl, p-nitrophenol, amino pyridine, or other convenient moiety.

The term "oligosaccharide," as used herein, means a linear or branched carbohydrate that consists of from 2 to about 50 monosaccharide units joined by means of glycosidic bonds. The monosaccharide units of an oligosaccharide are polyhydroxy alcohols containing either an aldehyde or a ketone group. An oligosaccharide can have, for example, up to 5, 10, 20, 30, 40 or 50 monosaccharide units. It is understood that "an oligosaccharide L-selectin antagonist" may have other non-carbohydrate components in addition to its carbohydrate component.

An L-selectin antagonist also can be a glycoconjugate or glycomimetic based on the structure Galβ1→4 (SO₃→6) GlcNAcβ1→3Galβ1→3GalNAc or NeuNAcα2→3Galβ1→4 [sulfo-6(Fucα1→3)GlcNAc]β1→3Galβ1→3GalNAcα1. Thus, an L-selectin antagonist of the invention can be a synthetic glycoconjugate or glycomimetic that retains the ability to inhibit binding of L-selectin to a MECA-79 antigen (Yarema and Bertozzi, Curr. Opin. Chem. Biol. 2:49-61 (1998); Dumitru, *supra*, 1996). Multivalent glycoconjugates are particularly useful L-selectin antagonists of the invention.

As disclosed herein, the MECA-79 epitope is formed, in part, by a core 1 extension enzyme ($\beta 1,3GnT$) which catalyzes the $\beta 1\rightarrow 3$ linkage of a GlcNAc residue to the core 1 structure ($Gal\beta 1\rightarrow 3GalNAc\rightarrow R$) and has the structure $Gal\beta 1\rightarrow 4(SO_3\rightarrow 6)GlcNAc\beta 1\rightarrow 3Gal\beta 1\rightarrow 3GalNAc$. Based on this discovery, the present invention provides an oligosaccharide L-selectin antagonist containing an extended core 1 structure which includes the oligosaccharide $Gal\beta 1\rightarrow 4(SO_3\rightarrow 6)GlcNAc\beta 1\rightarrow 3Gal\beta 1\rightarrow 3GalNAc$. In one embodiment, an isolated L-selectin antagonist contains the oligosaccharide $NeuNAc\alpha 2\rightarrow 3Gal\beta 1\rightarrow 4[sulfo\rightarrow 6(Fuc\alpha 1\rightarrow 3)GlcNAc]\beta 1\rightarrow 3Gal\beta 1\rightarrow 3GalNAc\alpha 1$. In another embodiment, an L-selectin antagonist contains multimers of one or both of the oligosaccharides $Gal\beta 1\rightarrow 4(SO_3\rightarrow 6)GlcNAc\beta 1\rightarrow 3Gal\beta 1\rightarrow 3GalNAc$ and $NeuNAc\alpha 2\rightarrow 3Gal\beta 1\rightarrow 4[sulfo\rightarrow 6(Fuc\alpha 1\rightarrow 3)GlcNAc]\beta 1\rightarrow 3Gal\beta 1\rightarrow 3GalNAc\alpha 1$. In addition to the structural features set forth above, an L-selectin antagonist inhibits L-selectin activity, for example, by competing for binding to physiological L-selectin ligand. L-selectin antagonists also include variants of these structures which cannot accept a GlcNAc residue at the 3 position of galactose, such as structures in which C-3 of galactose is deoxy; or variants in which GlcNAc contains a 6-dehydro group.

Other L-selectin antagonists can be core 1 structure derivatives which cannot accept a GlcNAc residue at the 3 position of galactose.

In a further embodiment, an L-selectin-mediated condition is treated or prevented by administering to the subject inhibitory antibody material that specifically binds $\beta 1,3GnT$. In yet a further embodiment, an L-selectin-mediated condition is treated or prevented by

administering to the subject a β 1,3GnT antisense nucleic acid molecule that has, for example, at least 20 nucleotides complementary to SEQ ID NO: 1 or SEQ ID NO: 3.

5 The present invention also provides an isolated polypeptide which contains an amino acid sequence encoding a L-selectin sulfotransferase-2 (LSST-2), or an active fragment thereof, that directs expression of a MECA-79 antigen in Chinese hamster ovary (CHO) cells. An
10 isolated polypeptide of the invention can have, for example, substantially the amino acid sequence of human LSST-2 (SEQ ID NO: 6).

As used herein, the term "isolated" means a polypeptide or nucleic acid molecule that is in a form
15 that is relatively free from contaminating lipids, polypeptides, nucleic acids or other cellular material normally associated with the nucleic acid molecule or polypeptide in a cell.

A LSST-2 polypeptide can have substantially the
20 amino acid sequence of SEQ ID NO: 6. Thus, an LSST-2 polypeptide of the invention can be the naturally occurring human LSST-2 (SEQ ID NO: 6), or a related polypeptide having substantial amino acid sequence similarity to this sequence. Such a related polypeptide
25 typically exhibits greater sequence similarity to human LSST-2 than to other sulfotransferases such as murine LSST, and includes isotype variants, alternatively spliced forms and species homologs of the amino acid sequence shown in Figure 4. As used herein, the term
30 "LSST-2" generally describes polypeptides having an amino

acid sequence with greater than about 50% identity, preferably greater than about 60% identity, more preferably greater than about 70% identity, and can be a polypeptide having greater than about 80%, 90%, 95%, 97%, 5 or 99% amino acid sequence identity with SEQ ID NO: 6, said amino acid identity determined with CLUSTALW using the BLOSUM 62 matrix with default parameters, provided that such a polypeptide is able to produce the MECA-79 antigen when expressed in CHO cells under the appropriate 10 conditions. The previously described murine polypeptide, LSST (Hiraoka et al., *supra*, 1999), which is not able to form the MECA-79 antigen when co-transfected into CHO cells with h β 1,3GnT, therefore is not a LSST-2 polypeptide of the invention.

15 The present invention also provides active fragments of a LSST-2 polypeptide. As used herein, the term "active fragment" means a polypeptide fragment having substantially the amino acid sequence of a portion of a LSST-2 that directs expression of a MECA-79 antigen 20 in CHO cells, provided that the fragment retains the sulfotransferase activity of the parent polypeptide as well as the ability to direct expression of a MECA-79 antigen in CHO cells. An active fragment of LSST-2 can have, for example, substantially the amino acid sequence 25 of a portion of human LSST-2 (SEQ ID NO:6). Sulfotransferase activity can be assayed, for example, as described in Hiraoka et al., Immunity 11:79-89 (1999). Activity in directing expression of a MECA-79 antigen can be assayed as set forth in Example IB.

As used herein, the term "substantially the amino acid sequence," when used in reference to a LSST-2

polypeptide or an active fragment thereof, is intended to mean a sequence as shown in Figure 4, or a similar, non-identical sequence that is considered by those skilled in the art to be a functionally equivalent amino acid sequence. For example, an amino acid sequence that has substantially the amino acid sequence of a human LSST-2 polypeptide (SEQ ID NO: 6) can have one or more modifications such as amino acid additions, deletions or substitutions relative to the amino acid sequence of SEQ ID NO: 6, provided that the modified polypeptide retains substantially the ability to direct expression of a MECA-79 antigen in CHO cells, as described further below.

Thus, it is understood that limited modifications can be made to a human LSST-2 polypeptide or another polypeptide of the invention (see below), or to an active fragment thereof without destroying its biological function. A modification can be, for example, an addition, deletion, or substitution of one or more conservative or non-conservative amino acid residues; substitution of a compound that mimics amino acid structure or function; or addition of chemical moieties such as amino or acetyl groups. The activity of a modified LSST-2 polypeptide or fragment thereof can be assayed by transfecting an encoding nucleic acid molecule into CHO cells and assaying for expression of MECA-79 as disclosed herein.

A particularly useful modification of a polypeptide of the invention, or fragment thereof, is a modification that confers, for example, increased stability. Incorporation of one or more D-amino acids is a modification useful in increasing stability of a

polypeptide or polypeptide fragment. Similarly, deletion or substitution of lysine can increase stability by protecting against degradation.

5 The present invention also provides substantially purified antibody material that specifically binds a LSST-2 that directs expression of a MECA-79 antigen in CHO cells. Such antibody material, which can be polyclonal or monoclonal antibody material,
10 specifically binds, for example, human LSST-2 having the amino acid sequence SEQ ID NO: 6.

A LSST-2 polypeptide or polypeptide fragment can be useful to prepare substantially purified antibody
15 material that specifically binds a LSST-2 which directs expression of a MECA-79 antigen in CHO cells. Such antibody material can be, for example, substantially purified polyclonal antiserum or monoclonal antibody material. The antibody material of the invention be
20 useful, for example, in determining the level of LSST-2 polypeptide in a subject.

As used herein, the term "antibody material" is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as polypeptide fragments
25 of antibodies that retain a specific binding activity for a LSST-2 polypeptide of at least about $1 \times 10^5 M^{-1}$. One skilled in the art would know that anti-LSST-2 antibody fragments such as Fab, F(ab')₂ and Fv fragments can retain specific binding activity for a LSST-2 polypeptide and,
30 thus, are included within the definition of antibody material. In addition, the term "antibody material," as used herein, encompasses non-naturally occurring

- antibodies and fragments containing, at a minimum, one V_H and one V_L domain, such as chimeric antibodies, humanized antibodies and single chain Fv fragments (scFv) that specifically bind a LSST-2 polypeptide. Such
- 5 non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, produced recombinantly or obtained, for example, by screening combinatorial libraries consisting of variable heavy chains and variable light chains as described by
- 10 Borrebaeck (Ed.), Antibody Engineering (Second edition) New York: Oxford University Press (1995)).

Antibody material "specific for" a LSST-2 polypeptide, or that "specifically binds" a LSST-2 polypeptide, binds with substantially higher affinity to

15 that polypeptide than to an unrelated polypeptide. The substantially purified antibody material of the invention also can bind with significantly higher affinity to a LSST-2 that directs expression of a MECA-79 antigen in CHO cells than to another sulfotransferase that does not

20 direct expression of a MECA-79 antigen in CHO cells.

Anti-LSST-2 antibody material can be prepared, for example, using a LSST-2 fusion protein or a synthetic peptide encoding a portion of a LSST-2 polypeptide such as SEQ ID NO: 6 as an immunogen. One skilled in the art would know that purified LSST-2 polypeptide, which can be produced recombinantly, or fragments of LSST-2, including peptide portions of LSST-2 such as synthetic peptides, can be used as an immunogen. Non-immunogenic fragments or synthetic peptides of LSST-2 can be made immunogenic

25 by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole limpet hemocyanin

30

(KLH). In addition, various other carrier molecules and methods for coupling a hapten to a carrier molecule are well known in the art are described, for example, by Harlow and Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1988)).

The term "substantially purified," as used herein in reference to antibody material, means that the antibody material is substantially devoid of polypeptides, nucleic acids and other cellular material which with an antibody is normally associated in a cell. The claimed antibody material that specifically binds an LSST-2 further is substantially devoid of antibody material of unrelated specificities, i.e. that does not specifically bind a LSST-2. The antibody material of the invention can be prepared in substantially purified form, for example, by LSST-2 affinity purification of polyclonal anti-LSST-2 antisera, by screening phage displayed antibodies against a LSST-2 polypeptide such as SEQ ID NO: 6, or as monoclonal antibodies prepared from hybridomas.

The present invention further provides an isolated nucleic acid molecule which contains a nucleic acid sequence encoding a LSST-2 or an active fragment thereof that directs expression of a MECA-79 antigen in CHO cells. An isolated nucleic acid molecule of the invention can encode, for example, a LSST-2 that has substantially the amino acid sequence of human LSST-2 (SEQ ID NO: 6) and can be, for example, SEQ ID NO: 5. The invention further provides vectors and related host cells that contain a nucleic acid molecule encoding a LSST-2 or active fragment thereof that directs expression

of a MECA-79 antigen in CHO cells. In one embodiment, such a vector is a mammalian expression vector.

The term "nucleic acid molecule" is used broadly to mean any polymer of two or more nucleotides, which are linked by a covalent bond such as a phosphodiester bond, a thioester bond, or any of various other bonds known in the art as useful and effective for linking nucleotides. Such nucleic acid molecules can be linear, circular or supercoiled, and can be single stranded or double stranded DNA or RNA or can be a DNA/RNA hybrid.

A sense or antisense nucleic acid molecule or oligonucleotide of the invention also can contain one or more nucleic acid analogs. Nucleoside analogs or phosphothioate bonds that link the nucleotides and protect against degradation by nucleases are particularly useful in a nucleic acid molecule or oligonucleotide of the invention. A ribonucleotide containing a 2-methyl group, instead of the normal hydroxyl group, bonded to the 2'-carbon atom of ribose residues, is an example of a non-naturally occurring RNA molecule that is resistant to enzymatic and chemical degradation. Other examples of non-naturally occurring organic molecules include RNA containing 2'-aminopyrimidines, such RNA being 1000x more stable in human serum as compared to naturally occurring RNA (see Lin et al., Nucl. Acids Res. 22:5229-5234 (1994); and Jellinek et al., Biochemistry 34:11363-11372 (1995)).

Additional nucleotide analogs also are well known in the art. For example, RNA molecules containing

2'-O-methylpurine substitutions on the ribose residues and short phosphorothioate caps at the 3'- and 5'-ends exhibit enhanced resistance to nucleases (Green et al., Chem. Biol. 2:683-695 (1995). Similarly, RNA containing 5 2'-amino- 2'-deoxypyrimidines or 2'-fluro-2'-deoxypyrimidines is less susceptible to nuclease activity (Pagratis et al., Nature Biotechnol. 15:68-73 (1997). Furthermore, L-RNA, which is a stereoisomer of naturally occurring D-RNA, is resistant to nuclease 10 activity (Nolte et al., Nature Biotechnol. 14:1116-1119 (1996); Klobmann et al., Nature Biotechnol. 14:1112-1115 (1996). Such RNA molecules and methods of producing them are well known and routine (see Eaton and Piekern, Ann. Rev. Biochem. 64:837-863 (1995). DNA molecules 15 containing phosphorothioate linked oligodeoxynucleotides are nuclease resistant (Reed et al., Cancer Res. 50:6565-6570 (1990). Phosphorothioate-3' hydroxypropylamine modification of the phosphodiester bond also reduces the susceptibility of a DNA molecule to 20 nuclease degradation (see Tam et al., Nucl. Acids Res. 22:977-986 (1994), which is incorporated herein by reference). Furthermore, thymidine can be replaced with 5-(1-pentynyl)- 2'-deoxoridine (Latham et al., Nucl. Acids Res. 22:2817-2822 (1994). It is understood that 25 nucleic acid molecules, including antisense molecules and oligonucleotides, containing one or more nucleotide analogs are encompassed by the invention.

The invention also provides vectors containing a nucleic acid molecule encoding a LSST-2. Such vectors 30 can be cloning vectors or expression vectors and provide a means to transfer an exogenous nucleic acid molecule into a host cell, which can be a prokaryotic or

eukaryotic cell. Contemplated vectors include those derived from a virus, such as a bacteriophage, a baculovirus or a retrovirus, and vectors derived from bacteria or a combination of bacterial and viral sequences, such as a cosmid or a plasmid. The vectors of the invention can advantageously be used to clone or express LSST-2 or an active fragment thereof. Various vectors and methods for introducing such vectors into a host cell are described, for example, in Ausubel et al., 5 Current Protocols in Molecular Biology John Wiley & Sons, 10 Inc. New York (1999).

In addition to a nucleic acid molecule encoding a LSST-2 or active fragment thereof, a vector of the invention also can contain, if desired, one or more of 15 the following elements: an oligonucleotide encoding, for example, a termination codon or a transcription or translation regulatory element; one or more selectable marker genes, such as an ampicillin, tetracycline, neomycin, hygromycin or zeomycin resistance gene, which 20 is useful for selecting stable transfecants in mammalian cells; one or more enhancer or promoter sequences, which can be obtained, for example, from a viral, bacterial or mammalian gene; transcription termination and RNA processing signals, which are obtained from a gene or a 25 virus such as SV40; an origin of replication such as an SV40, polyoma or *E. coli* origin of replication; versatile multiple cloning sites; and one or more RNA promoters such as a T7 or SP6 promoter, which allows for *in vitro* transcription of sense and antisense RNA.

30 In one embodiment, a vector of the invention is an expression vector. Expression vectors are well known

in the art and provide a means to transfer and express an exogenous nucleic acid molecule in a host cell.

Contemplated expression vectors include vectors that provide for expression in a host cell such as a bacterial 5 cell, yeast cell, insect cell, frog cell, mammalian cell or other animal cell. Such expression vectors include regulatory elements specifically required for expression of the DNA in a cell, the elements being located relative to the nucleic acid molecule encoding LSST-2 so as to 10 permit expression thereof. The regulatory elements can be chosen to provide constitutive expression or, if desired, inducible or cell type-specific expression.

Regulatory elements required for expression have been described above and include transcription and translation 15 start sites and termination sites. Such sites permit binding, for example, of RNA polymerase and ribosome subunits. A bacterial expression vector can include, for example, an RNA transcription promoter such as the lac promoter, a Shine-Delgarno sequence and an initiator AUG 20 codon in the proper frame to allow translation of an amino acid sequence.

Mammalian expression vectors can be particularly useful and can include, for example, a heterologous or homologous RNA transcription promoter for 25 RNA polymerase binding, a polyadenylation signal located downstream of the coding sequence, an AUG start codon in the appropriate frame and a termination codon to direct detachment of a ribosome following translation of the transcribed mRNA. Commercially available mammalian 30 expression vectors include pSI, which contains the SV40 enhancer/promoter (Promega; Madison, WI); pTarget™ and pCI, which each contain the cytomegalovirus (CMV)

- enhancer/promoter (Promega); pcDNA3.1, a CMV expression vector (Invitrogen; Carlsbad, CA); and pRc/RSV, which contains Rous sarcoma virus (RSV) enhancer/promoter sequences (Invitrogen). In addition to these 5 constitutive mammalian expression vectors, inducible expression systems are available, including, for example, an ecdysone-inducible mammalian expression system such as pIND and pVgRXR from Invitrogen. These and other mammalian expression vectors are commercially available 10 or can be assembled by those skilled in the art using well known methods. An example of a eukaryotic expression vector of the invention is pCDNA1.1/LSST-2, described in Example II below.

The invention also provides a host cell 15 containing a vector that includes a nucleic acid molecule encoding a LSST-2 or an active fragment thereof. Such a host cell can be used to replicate the vector and, if desired, to express and isolate substantially pure recombinant LSST-2 using well known biochemical 20 procedures (see Ausubel, *supra*, 1999). In addition, a host cell of the invention can be used in an *in vitro* or *in vivo* method to transfer sulfate to an acceptor molecule. Such host cells can be chosen or transfected to additionally co-express one or more additional enzymes 25 involved in oligosaccharide biosynthesis, for example, the core 1 extension enzyme, h β 1,3GnT. Such host cells can be used to prepare ligands having high affinity for the L-selectin glycoprotein receptor.

Host cells expressing LSST-2 or an active 30 fragment thereof also can be used to screen for selective inhibitors of LSST-2 or for agents that selectively react

with a L-selectin ligand. These agents can be administered to a subject to prevent or treat an L-selectin-mediated condition as described further below.

Examples of host cells useful in the invention 5 include bacterial, yeast, frog and mammalian cells. Various mammalian cells useful as host cells include, for example, mouse NIH/3T3 cells, CHO cells, COS cells and HeLa cells. In addition, mammalian cells obtained, for example, from a primary explant culture are useful as 10 host cells. Additional host cells include non-human mammalian embryonic stem cells, fertilized eggs and embryos, which can be routinely used to generate transgenic animals, such as mice, which express the novel LSST-2 of the invention. Transgenic mice expressing 15 LSST-2 can be used, for example, to screen for compounds that enhance or inhibit the MECA-79 producing activity of this enzyme. Methods for introducing a vector into a host including electroporation, microinjection, calcium phosphate, DEAE-dextran and lipofection methods well known in the art (see, for example, Ausubel, *supra*, 20 1999).

The invention also provides an isolated antisense nucleic acid molecule which contains a nucleotide sequence that specifically binds to SEQ ID 25 NO: 5, shown in Figure 4. Such an isolated antisense nucleic acid molecule can have, for example, at least 20 nucleotides complementary to SEQ ID NO: 5. In one embodiment, an isolated antisense nucleic acid molecule contains a nucleotide sequence complementary to the 30 sequence ATG.

An isolated antisense nucleic acid molecule can be useful to reduce LSST-2 expression, thereby treating or preventing an L-selectin-mediated condition in a subject. Antisense nucleic acid molecules can, for 5 example, reduce mRNA translation or increase mRNA degradation and thereby suppress gene expression (see, for example, Galderisi et al., J. Cell Physiol. 181:251-257 (1999)). Methods of using antisense nucleic acid molecules as therapeutic agents are well known in 10 the art (see Galderisi et al., *supra*, 1999; Alama et al., Pharmacol. Res. 36:171-178 (1997); and Temsamani et al., Biotechnol. Appl. Biochem. 26 (part 2):65-71 (1997))

The skilled artisan will recognize that effective reduction of LSST-2 expression depends upon the 15 antisense nucleic acid molecule having a high percentage of homology with the endogenous LSST-2 locus, for example, the endogenous human locus SEQ ID NO: 5. A nucleic acid molecule encoding human LSST-2 (SEQ ID NO: 5) provided herein is useful in the antisense methods 20 of the invention.

The homology requirement for effective suppression of gene expression using antisense methodology can be determined empirically. In general, a minimum of about 80-90% nucleic acid sequence identity is 25 preferred for effective suppression of LSST-2 expression. More preferably, a nucleic acid molecule that is exactly homologous to the gene to be suppressed is used as an antisense nucleic acid molecule. Both antisense oligonucleotides of 20, 22, 25, 30, 35, 40 or more 30 nucleotides, as well as antisense nucleic acid molecules

is expressed in a vector are contemplated for use in the antisense methods of the invention.

Also provided herein is an oligonucleotide, which contains a nucleotide sequence having at least 10 5 contiguous nucleotides of SEQ ID NO: 5, or a nucleotide sequence complementary thereto. An oligonucleotide of the invention can have, for example, at least 15 contiguous nucleotides of SEQ ID NO: 5, or a nucleotide sequence complementary thereto.

10 Oligonucleotides of the invention can advantageously be used, for example, as primers for PCR or sequencing, as probes for research or diagnostic applications, and in therapeutic applications. An oligonucleotide of the invention can incorporate, if 15 desired, a detectable moiety such as a radiolabel, fluorochrome, luminescent tag, ferromagnetic substance, or a detectable agent such as biotin, and used to detect expression of LSST-2 in a cell or tissue. Those skilled in the art can determine the appropriate length and 20 nucleic acid sequence of a LSST-2 oligonucleotide for a particular application. An oligonucleotide of the invention contains a nucleotide sequence having, for example, at least, 10, 12, 14, 16, 18, 20, 25, 30, 35 or 40 contiguous nucleotides of SEQ ID NO: 5, or a 25 nucleotide sequence complementary thereto.

The present invention also provides a method of modifying an acceptor molecule by contacting the acceptor molecule with an isolated LSST-2, or an active fragment thereof, under conditions that allow addition of a 30 sulfate to a GlcNAc acceptor molecule, where the LSST-2

or active fragment thereof directs expression of a MECA-79 antigen in CHO cells. A LSST-2 useful for modifying an acceptor molecule according to a method of the invention can have, for example, substantially the 5 amino acid sequence of human LSST-2 (SEQ ID NO: 6) or an active fragment thereof. In a method of the invention, an isolated LSST-2 can add a sulfate to the 6-position of GlcNAc.

The term "acceptor molecule," as used herein, 10 refers to a molecule that is acted upon, or "modified," by a protein having enzymatic activity. For example, an acceptor molecule can be a molecule that accepts the transfer of a sulfate due to the sulfotransferase activity of a LSST-2 polypeptide. An acceptor molecule 15 can be in substantially pure form or in an impure form such as in a host cell or cellular extract. An acceptor molecule can be a naturally occurring molecule or a completely or partially synthesized molecule. An acceptor molecule can contain one or more sugar residues 20 prior to modification and can be further modified to contain additional sugar residues. An acceptor molecule useful in the invention contains the core 1 structure (Gal β 1-3GalNAc-R) and can be, for example, CD34 as disclosed herein. Additional acceptor molecules include 25 podocalyxin, Sgp200 and GlyCAM-1.

In one embodiment, the invention provides a method of modifying an acceptor molecule by contacting the acceptor molecule with an isolated LSST-2 or an active fragment thereof in combination with an isolated 30 β 1,3GnT that directs expression of a MECA-79 antigen under conditions that allow addition of core 1 GlcNAc

linkages and sulfate to the acceptor molecule such that a MECA-79 antigen is formed. As disclosed herein, human β 1,3GnT (SEQ ID NO: 2) and human LSST-2 (SEQ ID NO: 6) can be used together to modify a core 1 structure to 5 produce the MECA-79 antigen,
 $\text{Gal}\beta\text{1}\rightarrow 4(\text{SO}_3\rightarrow 6)\text{GlcNAc}\beta\text{1}\rightarrow 3\text{Gal}\beta\text{1}\rightarrow 3\text{GalNAc}$, in CHO cells.

The invention also provides a method of treating or preventing an L-selectin-mediated condition in a subject by reducing the expression or activity of a 10 LSST-2 that directs expression of a MECA-79 antigen in CHO cells. L-selectin-mediated conditions as well as techniques for reducing the expression or activity of an enzyme such as LSST-2 are described hereinabove.

As further disclosed herein in Example V, the 15 mouse intestinal GlcNAc 6-sulfotransferase can, in combination with a β 1,3GnT, form the MECA-79 antigen in Lec2 cells, but not in CHO cells. In these cells, which are defective in Golgi sialylation, more core 1 extension product is formed by the core 1 extension enzyme, 20 β 1,3GnT. Under these conditions, murine intestinal GlcNAc 6-sulfotransferase (I-GlcNAc6ST) adds enough sulfate to form the MECA-79 antigen. Thus, the invention also provides a novel nucleic acid molecule that contains 25 a nucleic acid sequence encoding substantially the amino acid sequence of I-GlcNAc6ST or an active fragment thereof. An isolated nucleic acid molecule of the invention can encode, for example, substantially the amino acid sequence of SEQ ID NO: 8 and can be, for example, SEQ ID NO: 7. In one embodiment, an isolated 30 nucleic acid molecule of the invention encodes

substantially the amino acid sequence of SEQ ID NO: 8, provided that the nucleic acid molecule is not AI115260.

- The invention also provides an isolated
- 5 polypeptide that contains an amino acid sequence encoding substantially the amino acid sequence of intestinal GlcNAc 6-sulfotransferase (I-GlcNAc6ST) or an active fragment thereof. Such a polypeptide of the invention can have, for example, substantially the amino acid
- 10 sequence of SEQ ID NO: 8.

An I-GlcNAc6ST polypeptide has substantially the amino acid sequence of SEQ ID NO: 8. Thus, an I-GlcNAc6ST polypeptide of the invention can be the naturally occurring I-GlcNAc6ST (SEQ ID NO: 8), or a

15 related polypeptide having substantial amino acid sequence similarity to this sequence. Such a related polypeptide includes isotype variants, alternatively spliced forms and species homologs of the amino acid sequence shown in Figure 10. As used herein, the term

20 "I-GlcNAc6ST" generally describes polypeptides having an amino acid sequence with greater than about 50% identity, preferably greater than about 60% identity, more preferably greater than about 70% identity, and can be a polypeptide having greater than about 75%, 80%, 85%, 90%,

25 95%, 97%, or 99% amino acid sequence identity with SEQ ID NO: 8, said amino acid identity determined with CLUSTALW using the BLOSUM 62 matrix with default parameters, provided that such a polypeptide is able to produce the MECA-79 antigen when expressed in Lec2 cells under the

30 appropriate conditions. The previously described murine polypeptide, LSST (Hiraoka et al., *supra*, 1999) is not an I-GlcNAc6ST polypeptide of the invention.

The present invention also provides active fragments of an I-GlcNAc6ST polypeptide. As used herein, the term "active fragment," when used in reference to an I-GlcNAc6ST polypeptide, means a polypeptide fragment 5 having substantially the amino acid sequence of a portion of an I-GlcNAc6ST, provided that the fragment retains the 6-sulfotransferase activity of the parent polypeptide as well as the ability to direct expression of a MECA-79 antigen when expressed in Lec2 cells. An active fragment 10 can have, for example, substantially the amino acid sequence of a portion of murine I-GlcNAc6ST (SEQ ID NO:8). Sulfotransferase activity can be assayed, for example, as described in Hiraoka et al., Immunity 11:79-89 (1999). Activity in directing expression of a 15 MECA-79 antigen can be assayed as set forth in Example IB.

Furthermore, the term "substantially the amino acid sequence," when used in reference to an I-GlcNAc6ST 20 polypeptide or an active fragment thereof, is intended to mean a sequence as shown in Figure 10, or a similar, non-identical sequence that is considered by those skilled in the art to be a functionally equivalent amino acid sequence. For example, an amino acid sequence that 25 has substantially the amino acid sequence of an I-GlcNAc6ST polypeptide (SEQ ID NO: 8) can have one or more modifications such as amino acid additions, deletions or substitutions relative to the amino acid sequence of SEQ ID NO: 8, provided that the modified 30 polypeptide retains substantially 6-sulfotransferase activity as well as the ability to direct expression of a MECA-79 antigen in Lec2 cells (see Example V).

In addition, the invention also provides substantially purified antibody material that specifically binds an isolated polypeptide having an amino acid sequence encoding substantially the amino acid sequence of I-GlcNAc6ST or an active fragment thereof. Such antibody material, which can be polyclonal or monoclonal antibody material, specifically binds, for example, murine I-GlcNAc6ST having the amino acid sequence SEQ ID NO: 8. Thus, such antibody material includes polyclonal and monoclonal antibodies, as well as polypeptide fragments of antibodies that retain a specific binding activity for an I-GlcNAc6ST polypeptide of at least about $1 \times 10^5 \text{ M}^{-1}$. As set forth above, such antibody material includes Fab, $F(ab')_2$, and Fv fragments as well as chimeric and humanized antibodies and single chain Fv fragments (scFv) that specifically bind an I-GlcNAc6ST polypeptide of the invention.

The present invention further provides an isolated nucleic acid molecule which contains a nucleic acid sequence encoding an I-GlcNAc6ST or an active fragment thereof. An isolated nucleic acid molecule of the invention can encode, for example, an I-GlcNAc6ST having substantially the amino acid sequence of murine I-GlcNAc6ST (SEQ ID NO: 8) and can be, for example, SEQ ID NO: 7. The invention further provides vectors and related host cells that contain a nucleic acid molecule encoding an I-GlcNAc6ST or active fragment thereof. In one embodiment, the vector is a mammalian expression vector. As set forth above, a variety of vectors, including cloning and expression vectors, and host cells are well known in the art.

The invention also provides an isolated antisense nucleic acid molecule which contains a nucleotide sequence that specifically binds to SEQ ID NO: 7, shown in Figure 10. Such an isolated antisense nucleic acid molecule can have, for example, at least 20 nucleotides complementary to SEQ ID NO: 7. In one embodiment, an isolated antisense nucleic acid molecule contains a nucleotide sequence complementary to the sequence ATG. An antisense nucleic acid molecule can have, for example, 20, 22, 25, 30, 35, 40 or more nucleotides.

Also provided herein is an oligonucleotide, which contains a nucleotide sequence having at least 10 contiguous nucleotides of SEQ ID NO: 7, or a nucleotide sequence complementary thereto. An oligonucleotide of the invention can have, for example, at least 15 contiguous nucleotides of SEQ ID NO: 7, or a nucleotide sequence complementary thereto.

As set forth above, a sense or antisense nucleic acid molecule or oligonucleotide of the invention is a polymer of two or more nucleotides, which are linked by a covalent bond such as a phosphodiester bond, a thioester bond, or any of various other bonds known in the art as useful and effective for linking nucleotides. Furthermore, a nucleic acid molecule or oligonucleotide of the invention can contain one or more nucleic acid analogs (see above). An oligonucleotide of the invention contains a nucleotide sequence having, for example, at least, 10, 12, 14, 16, 18, 20, 25, 30, 35 or 40 contiguous nucleotides of SEQ ID NO: 7, or a nucleotide sequence complementary thereto.

The present invention also provides a method of modifying an acceptor molecule by contacting the acceptor molecule with an isolated I-GlcNAc6ST, or an active fragment thereof, under conditions that allow addition of 5 a sulfate to a GlcNAc acceptor molecule.

The following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

10 CLONING AND CHARACTERIZATION OF THE HUMAN CORE 1
EXTENSION ENZYME, β 1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE
(β 1,3GnT)

This example describes the cloning and characterization of human and murine β 1,3-N-acetylglucosaminyltransferase (β 1,3GnT).

15 A. Cloning and characterization of human β 1,3GnT

Sequences homologous among β 1,3-galactosyl-transferases and β 1,3-N-acetylglucosaminyltransferases shown in Figure 5 (Zhou et al., Proc. Natl. Acad. Sci., USA 96:406-411 (1999)) were used as probes to search 20 dbEST using the tblastn program. An EST clone (AB015630) containing a single open reading frame of 372 amino acids was obtained. Primers 5'-CTGGCTGCCAGGATGAAGTATCTCC-3' (β 1,3GnT-A1; SEQ ID NO: 9) and 5'-CCTGATGCTGACTCAGTAGATCTGTGTC-3' (β 1,3GnT-A2AS; SEQ ID NO: 10) were designed based on EST AB015630. After 25 amplification of single-stranded cDNA prepared from HT29 cells using the Thermoscript RT-PCR system (Gibco-BRL #11146-024; Baithersburg, MD), a 1.2 kb fragment

containing full-length coding sequence was isolated (see Figure 2). The 1.2 Kb fragment containing the full-length human β 1,3GnT cDNA was subcloned into the mammalian expression vector pcDNA3.1 (Invitrogen) and 5 designated pcDNA3.1/h β 1,3GnT-A.

In order to characterize the human β 1,3GnT enzyme, a soluble form of the enzyme was prepared by amplifying amino acids 44 to 372 with PCR primers 5'-CGGGATCCCGAGGCCCTGGCCTGGCCCCTCC-3' (β 1,3GnT-A-5'Bam; 10 SEQ ID NO: 11) and 5'-GCTCTAGACTCAGTAGATCTGTGTCTGATTGC-3' (β 1,3GnT-A-3'AS-Xba; SEQ ID NO: 12) and subsequently cloning the amplified fragment into the *Bam*HI and *Xba*I sites of pcDNA3.1/HSH, a modified vector based on pcDNA3.1/Hydro (Invitrogen) and containing a signal 15 peptide followed by a 6 histidine tag. This vector (4 μ g) was transfected into Chinese hamster ovary (CHO) cells using lipofectamine PLUS (Gibco-BRL #10964-013). As a negative control, CHO cells were mock transfected with a vector lacking the β 1,3GnT sequence.

20 Media from cells expressing the soluble enzyme or mock transfected were collected and concentrated essentially as described in Yeh et al., J. Biol. Chem. 274:3215-3221 (1999). For analysis of β 1,3-galactosyltransferase activity, 3 H-UDP-galactose was 25 used as the sugar nucleotide donor and GalNAc- α -pNP and GlcNAc- β -pNP were used as oligosaccharide acceptor molecules. For detection of β 1,3-N-acetylglucosaminyltransferase (β 1,3GnT) activity, 3 H-UDP-GlcNAc was used as the sugar nucleotide donor with 30 the following oligosaccharide acceptor molecules: Gal β 1,3Glc- β -pNP; core 1 pNP (Gal β 1,3GalNAc- α -pNP);

core 2 pNP ($\text{Gal}\beta 1,3(\text{GlcNAc}\beta 1,6)\text{GalNAc}-\alpha-\text{pNP}$) ; Gal- α -pNP and Gal- β -pNP.

Supernatant from cells expressing the soluble enzyme or mock transfected was assayed for *in vitro* 5 enzyme activity. As shown in Figure 6, concentrated medium from soluble enzyme transfected cells was found to have activity in transferring ^3H -UDP-GlcNAc to core 1-pNP and core 2-pNP. These results indicate that the cloned enzyme has activity as a core 1 extension 10 $\beta 1,3$ -N-acetylglucosaminyltransferase.

B. Production of the MECA-79 antigen using recombinant $h\beta 1,3\text{GnT}$ (SEQ ID NO: 2)

CHO cells were transfected with CD34 and either (a) no enzyme; (b) pcDNA1/hLSST-2 alone; 15 pcDNA3.1/Zeo/m $\beta 1,3\text{GnT}$ alone; or pcDNA1/hLSST-2 and pcDNA3.1/Zeo/m $\beta 1,3\text{GnT}$ together using lipofectamine essentially as described above. Mock transfected and transfected cells were stained with MECA-79 antibody obtained from Pharmingen (San Diego, CA), and further 20 incubated with goat anti-rat IgM antibodies essentially as described in Hemmerich et al., *supra*, 1994. As shown in Figure 7, positive staining with MECA-79 antibody was only observed in cells co-transfected with both hLSST-2 and m $\beta 1,3\text{GnT}$ vectors, but not in cells only transfected 25 with either enzyme alone. No other sulfotransferases examined showed MECA-79 expression when cotrasnfected into CHO cells with m $\beta 1,3\text{GnT}$. These results indicate that the human L-selectin sulfotransferase-2 and the core 1 extension enzyme $\beta 1,3\text{GnT}$ are sufficient to form the 30 MECA-79 antigen when co-expressed in CHO cells.

C. Cloning and characterization of murine β 1,3GnT

Several sets of primers based on the human core 1 extension β 1,3GnT were used for PCR amplification of single stranded cDNA prepared from mouse small intestine using a SMART PCR cDNA synthesis kit according to the manufacturer's instructions (Clontech #K1052-1). PCR amplification was performed using the following conditions: 94°C for 2 minutes, followed by 35 cycles of 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute. Only one set of primers gave a specific amplification product. Primers A7 (5'-TTCCTGCTGCTGGTGATCAAGTCC-3'; SEQ ID NO: 13), which corresponds to human β 1,3GnT nucleotides 335 to 358) and primer A3AS (5'-CAGGACCTGCTTGAGCGTGAGGTTG-3'; SEQ ID NO: 14), which corresponds to human β 1,3GnT nucleotides 560 to 585, gave a product of 251 bp.

5'- and 3'-RACE were performed to isolate additional murine β 1,3GnT sequence. 5'-RACE was performed using Marathon-Ready mouse testis cDNA (Clontech) using mA2AS primer 5'-ATGGAAATCCCCTGGAGAATGTGCCGT-3' (SEQ ID NO: 15) and the AP1 primer provided by Marathon-Ready cDNA kit. 3'-RACE was performed using mA1 primer 5'-GCCTGCCTAACTATGGGCGCCGCCAGAT-3' (SEQ ID NO: 16) and the SMART primer (Clontech) on mouse small intestine single stranded cDNA prepared using Clontech's SMART PCR cDNA synthesis kit as a template. The full-length cDNA was amplified based on the RACE sequence from mouse small intestine single-stranded cDNA and subcloned into pcDNA3.1/Zeo and designated pcDNA3.1/Zeo/m β 13,GnT.

EXAMPLE II**CLONING OF HUMAN L-SELECTIN LIGAND SULFOTRANSFERASE
(LSST-2)**

5 This example describes the isolation of a nucleic acid molecule encoding human L-selectin ligand sulfotransferase-2 (LSST-2), which, together with the β 1,3-N-acetylglucosaminyltransferase, directs expression of the MECA-79 antigen.

10 Like other sulfotransferases in the same gene family (Mazany et al., *Biochim. Biophys. Acta* 1407:92-97 (1998)), the coding sequence for human LSST-2 was expected to reside in a single exon. Thus, human genomic DNA was used as the template for PCR-based cloning.

15 Primers corresponding to nucleotides 891 to 910 and nucleotides 1327-1302 of mouse LSST-1 (Hiraoka et al., *supra*, 1999) were used to amplify human genomic DNA as follows. Samples were denatured for 3 minutes at 94°C, followed by 40 cycles of 1 minute at 94°C, 30 seconds at 20 61°C, and 45 seconds at 72°C. The amplified products were cloned into pBluescript by TA cloning. The resultant coding sequence was 79.2% identical to mouse LSST-1 at the nucleotide level.

To clone the full-length LSST-2 coding sequence, a P1 phage library of human genomic DNA (Genome System Inc.; St. Louis, MO) was PCR-amplified using primers 5'-CCGAATTCTCCCGAGAACGACAAAG-3' (SEQ ID NO: 17) and 5'-CCCAAGCTTCTCATAGCGCACAAAGCAG-3' (SEQ ID NO: 18). The PCR was carried out for 30 cycles using a 67°C annealing temperature. From the single positive clone, 30 DNA was purified and sequenced directly. The coding

sequence present on the single exon was confirmed by reverse transcriptase (RT)-PCR using poly(A)⁺ RNA isolated from human lymph node, as described previously (Hiraoka et al., *supra*, 1999). Three pairs of primers used in
5 these PCR reactions correspond to
5'-TTGGCCAGAAGGGGAATAG-3' (SEQ ID NO: 19) and
5'-CCACTGAAAGAGGCTGGACTGT-3' (SEQ ID NO: 20);
5'-GGTTCTGTCTTCCTGGCGCTC-3' (SEQ ID NO: 21) and
5'-TTTGGCAGATGACCTGCATCAC-3' (SEQ ID NO: 22); and
10 5'-AGAACGCACAAAGGAGATCTCA-3' (SEQ ID NO: 23) and
5'-AGATGTAGGCAAGGCTCAGAAG-3' (SEQ ID NO: 24). PCR with
the first two pairs of primers was performed by
denaturation for 3 minutes at 94°C, followed by 35 cycles
of 1 minute at 94°C, 30 seconds at 56°C, and 1 minute at
15 72°C. For the PCR with the third pair of primers, the
annealing temperature was changed to 55°C. With the
first pair of primers (SEQ ID NOS: 19 and 20), the
expected characteristic fragment of 470 bp was obtained.
With the second pair of primers (SEQ ID NOS: 21 and 22),
20 the expected characteristic fragment of 617 bp was
obtained. With the third pair of primers (SEQ ID NOS: 23
and 24), the expected characteristic fragment of 600 bp
was obtained.

The cDNA containing full-length coding sequence
25 of human LSST-2 was excised by *Xba*I and *Tfi*I, blunt-ended
and cloned into pcDNA1.1 (Invitrogen). The resulting
LSST-2 expression vector, in which the LSST-2 coding
sequence is expressed under control of the CMV promoter,
was designated pcDNA1.1/LSST-2.

EXAMPLE IIIFUNCTIONAL ANALYSIS OF HUMAN β 1,3GnT

This example describes the function of h β 1,3GnT when stably expressed in CHO cells with hLSST-2.

5 The following CHO cell lines were generated by stable transfection: CHO/CD34/FT7/hLSST-2; CHO/CD34/FT7/hLSST-2/C2GnT-L; CHO/CD34/FT7/hLSST-2/core 1 extension β 1,3GnT; and CHO/CD34/FT7/hLSST-2/C2GnT-L/core 1 extension β 1,3GnT.

10 The stable cell lines were established by standard procedures. Cells were selected with a combination of neomycin, hygromycin and zeocin. The expression of each gene was confirmed by immunostaining with specific antibodies against the 15 relevant cell surface antigens.

Expression of human CD34 was confirmed by the positive staining of cells with anti-human CD34 antibody. CHO/CD34/FT7/hLSST-2 was first established. The expression of human fucosyltransferase 7 (FT7) was 20 confirmed by the positive staining of cells with anti-sialyl Lewis x (product of FT7) antibody 2H5 as described in Kimura et al., Proc. Natl. Acad. Sci., USA 96:4530-4535 (1997). Expression of hLSST-2 was confirmed by transient transfection of β 1,3GnT-A (core 1 25 extension β 1,3GnT) and cells were stained with MECA-79 as described above. For the confirmation of C2GnT expression in the CHO/CD34/FT7/hLSST/C2GnT-L cell line, the NCC-ST-439 antibody against sialyl Lewis x core 2 structure was used essentially as described in Kumamoto

et al., Biochim. Biophys. Res. Comm. 247:514-517 (1998). For the confirmation of core 1 extension β 1,3GnT expression in the CHO/CD34/FT7/hLSST/core 1 extension β 1,3GnT cell line, MECA-79 antibody staining 5 was performed as described above.

Cells were grown as a monolayer on tissue culture flasks, and mouse lymphocytes were allowed to flow over the monolayer under different shear forces essentially as described in Fuhlbrigge et al., J. Cell Biol. 135:837-48 (1996). The number of lymphocytes which rolled on the cell monolayer were monitored by video camera and counted. As shown in Figure 8, CHO cells expressing either the core 2 extension enzyme, C2GnT-L (open square) or the human core 1 extension enzyme, 10 β 1,3GnT (filled square) rolled more than cells only expressing fucosyltransferase VII (FT7; open circle). Furthermore, rolling was significantly enhanced when lymphocytes rolled on cells expressing both the core 2 15 extension enzyme, C2GnT-L, and human β 1,3GnT (filled circle). These results indicate that both core 1 and 20 core 2 extended sulfo sialyl Lewis X determinants play a role in lymphocyte homing.

EXAMPLE IV

DEFINITION OF THE MINIMUM EPITOPE OF THE MECA-79 ANTIGEN

25 This example describes the use of ELISA analysis to define the minimum epitope of the MECA-79 antigen.

A. ELISA Assays with anti-MECA-79 Antibody

The stable CHO transfectants described in Example III were grown on 10 cm plates and transiently transfected with soluble form of human CD34 (pcDNA3.1/HSH vector) using LipofectAmine PLUS (GibcoBRL). One day after transfection, the culture media was replaced with 10 ml of OptiMEM reduced-serum medium. After culturing for an additional two days, the culture media was collected. Cell debris was removed by centrifugation, and the media was concentrated 10-fold by Centriprep 10 concentrators.

The concentrated media was diluted 100-fold in Tris-buffered saline (TBS; 50 mM Tris, 150 mM NaCl, pH 7.5). The wells of 96-well polystyrene microtiter plates (Nunc, F96 Maxisorp Cat. # 442404) were coated overnight with 100 µl of diluted media at 4°C. The plates were washed three times with TBS and were blocked with 250 µl of 5% BSA (in TBS) at room temperature for at least two hours (or 4°C overnight). The wells were washed three times with washing buffer (TBS containing 0.1% Tween 20). Two-fold serially diluted MECA-79 antibody at a concentration of 1:200 to 1:12,800 (Pharmingen) was prepared in dilution buffer (5% BSA in washing buffer). Fifty µl of diluted antibodies were added to each well and incubated at room temperature for one hour. After washing three times with washing buffer, 50 µl of anti-rat IgM-alkaline phosphatase conjugate (1:500 in dilution buffer) was added to each well and allowed to incubate at room temperature for one hour. Following washing three times with washing buffer, the wells were washed twice with deionized water. Alkaline

phosphatase substrate p-nitro-phenylphosphate (1 mg/ml) was freshly prepared in bicarbonate buffer (0.1 M NaHCO₃, pH 9.6) containing 0.5 mM MgCl₂. Fifty microliter of this substrate solution was added to each well and allowed to
5 incubate at 37°C. The optical density at 405 nm of each well was recorded using Spectra MAX Plus microtiter plate reader (Molecular Device Corp.). Positive readings were observed from the media of CHO cells harboring both hLSST-2 and core 1 extension β 1,3GnT and
10 CHO/CD34/FT7/hLSST-2/core 1 extension β 1,3GnT/core2GnT).

B. Inhibition of MECA-79 Antibody Binding by Synthetic Oligosaccharides

Synthetic oligosaccharides were mixed at the indicated concentrations with MECA-79 antibody (at a
15 final dilution of 1:10,000). The mixtures were incubated at room temperature for one hour before addition to wells precoated with transfected media from CHO/CD34/FT7/LSST/core 1 extension β 1,3GnT cells as above. Antibody binding was assayed as described above.

20 The results shown in Figure 9 indicate that only the 6-S-extended core 1 structure (Gal β 1 \rightarrow 4(SO₃ \rightarrow 6) GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc) was active in inhibiting binding of anti-MECA-79 antibody. Thus, these results define the minimum epitope of MECA-79 as Gal β 1 \rightarrow 4(SO₃ \rightarrow 6)
25 GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc.

To further confirm and refine the requirements for the MECA-79 reactivity, oligosaccharides derived from the extended core 1 glycan were chemically synthesized and examined for their ability to inhibit MECA-79

antibody binding to MECA-79-reactive CD34 chimeric proteins. MECA-79 antibody binding was efficiently inhibited by a 6-sulfo extended core 1 oligosaccharide, Gal β 1 \rightarrow 4(sulfo \rightarrow 6)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc α 1-octyl, and its 5 sialylated or sialylated, fucosylated forms, NeuNAc α 2 \rightarrow 3Gal β 1 \rightarrow 4[Fuc α 1 \rightarrow 3(sulfo \rightarrow 6)]GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc α 1-octyl (see Figure 9). The 6-sulfo group was absolutely required, since non-sulfated, extended core 1 oligosaccharide did not inhibit MECA-79 antibody binding 10 (Figure 9). In addition, the terminal galactose residue in the N-acetyllactosaminyl core 1 was part of the epitope, since the agalacto form required more than a 10-fold increase concentration to achieve equivalent inhibition (Figure 9). An absolute requirement for core 15 1 structure was also demonstrated, since sulfated N-acetyllactosamine lacking a core 1 structure did not show detectable inhibition. These results are consistent with previous studies showing that sialic acid and fucose are not integral parts of the MECA-79 epitope (Hemmerich 20 et al., *supra*, 1994; Maly et al., *supra*, 1996). The results also are consistent with previous findings that the MECA-79 antibody can inhibit lymphocyte homing without prior removal of sialic acid or fucose (Streeter et al., *supra*, 1988; Clark et al., *J. Biol. Chem.* 25 140:721-731 (1998)).

These results demonstrate that the minimum epitope of MECA-79 is the sulfated, extended core 1 structure Gal β 1 \rightarrow 4(sulfo \rightarrow 6)GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 3GalNAc α 1 \rightarrow R, and that sialylated and sialylated, fucosylated forms of 30 this structure (6-sulfo sLe* in extended core 1 forms) retain MECA-79 reactivity.

EXAMPLE V**MURINE INTESTINAL GlcNAc 6-SULFOTRANSFERASE**

This example describes the cloning and characterization of the murine intestinal GlcNAc 6-sulfotransferase.

The coding sequence of mouse LSST-1 (Hiraoka et al., Immunity 11:79-89 (1999)) was used as probe to search dbEST using tblstx program. One unknown query gene (AI115260) was found to have 53.8% identity with the 10 coding regions of mouse LSST-1. AI115260 is a sequence isolated from mouse embryo cDNA. Sequence analysis of this cDNA, obtained from Genome Systems (St. Louis, MS), revealed that this cDNA encodes a protein of 396 amino acids, designated intestinal GlcNAc 6-sulfotransferase. 15 The cDNA insert was digested with EcoRI and XbaI and cloned into the corresponding sites of pcDNA3.1 (Invitrogen) to produce the expression vector pCDNA3-I-GlcNAc6ST.

Lec2 cells, which are defective in Golgi 20 sialylation due to a CMP-sialic acid transporter defect, were doubly transfected with pcDNA3-I-GlcNAc6ST and pCDNA3.1/h β 1,3GnT-A. Because of the absence of sialic acid in Lec2 cells, core 1 extension occurs with the competition of sialylation and, therefore, more core 1 25 extended structure is formed by the core 1 extension enzyme β 1,3GnT. Under these conditions, the MECA-79 antigen was produced in the doubly transfected Lec2 cells. Similar production of MECA-79 antigen was observed when Lec2 cells were doubly transfected with 30 mLSST-1 and h β 1,3GnT (SEQ ID NO: 2). These results

indicate that, under certain conditions, mLSST-1 or I-GlcNAc6ST can form the MECA-79 antigen.

All journal article, reference, and patent citations provided above, in parentheses or otherwise,
5 whether previously stated or not, are incorporated herein by reference.

Although the invention has been described with reference to the examples above, it should be understood that various modifications can be made without departing
10 from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

We claim:

1. A method of treating or preventing an L-selectin-mediated condition in a subject, comprising reducing the expression or activity of a $\beta 1,3GnT$ that 5 directs expression of a MECA-79 antigen.

2. The method of claim 1, comprising administering to said subject an oligosaccharide L-selectin antagonist that inhibits the binding of L-selectin to a MECA-79 antigen.

10 3. The method of claim 2, wherein said L-selectin antagonist comprises the oligosaccharide Gal $\beta 1\rightarrow 4$ (SO₃ $\rightarrow 6$)GlcNAc $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc.

4. The method of claim 3, wherein said L-selectin antagonist comprises
15 NeuNAc $\alpha 2\rightarrow 3$ Gal $\beta 1\rightarrow 4$ [sulfo $\rightarrow 6$ (Fuc $\alpha 1\rightarrow 3$)GlcNAc] $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc $\alpha 1$.

5. The method of claim 3, wherein said L-selectin antagonist comprises two or more of the oligosaccharide Gal $\beta 1\rightarrow 4$ (SO₃ $\rightarrow 6$)GlcNAc $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc.

20 6. The method of claim 4, wherein said L-selectin antagonist comprises two or more of the oligosaccharide
NeuNAc $\alpha 2\rightarrow 3$ Gal $\beta 1\rightarrow 4$ [sulfo $\rightarrow 6$ (Fuc $\alpha 1\rightarrow 3$)GlcNAc] $\beta 1\rightarrow 3$ Gal $\beta 1\rightarrow 3$ GalNAc $\alpha 1$.

7. The method of claim 1, comprising administering to said subject inhibitory antibody material that specifically binds $\beta 1,3\text{GnT}$.
8. The method of claim 1, comprising 5 administering to said subject a $\beta 1,3\text{GnT}$ antisense nucleic acid molecule.
9. The method of claim 8, wherein said antisense nucleic acid molecule has at least 20 nucleotides complementary to SEQ ID NO: 1.
10. The method of claim 9, wherein said antisense nucleic acid molecule has at least 20 nucleotides complementary to SEQ ID NO: 3.
11. The method of claim 1, further comprising reducing the expression or activity of L-selectin 15 sulfotransferase-2 (LSST-2) in said subject.
12. An isolated L-selectin antagonist, comprising an extended core 1 structure comprising the oligosaccharide $\text{Gal}\beta 1\rightarrow 4(\text{SO}_3\rightarrow 6)\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 3\text{GalNAc}$.
13. The isolated L-selectin antagonist of 20 claim 12, comprising the oligosaccharide $\text{NeuNAc}\alpha 2\rightarrow 3\text{Gal}\beta 1\rightarrow 4[\text{sulfo-}6(\text{Fuc}\alpha 1\rightarrow 3)\text{GlcNAc}]\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 3\text{GalNAc}$.
14. The isolated L-selectin antagonist of 25 claim 12, comprising two or more of the oligosaccharides $\text{Gal}\beta 1\rightarrow 4(\text{SO}_3\rightarrow 6)\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 3\text{GalNAc}$.

15. The isolated L-selectin antagonist of
claim 13, comprising two or more of the oligosaccharides
NeuNAc α 2-3Gal β 1-4[sulfo-6(Fuc α 1-3)GlcNAc] β 1-3Gal β 1-3GalNA
 α 1.

5 16. An isolated nucleic acid molecule,
comprising a nucleic acid sequence encoding a L-selectin
ligand sulfotransferase (LSST-2) or active fragment
thereof, wherein said LSST-2 or active fragment thereof
directs expression of a MECA-79 antigen in Chinese
10 hamster ovary (CHO) cells.

17. The isolated nucleic acid molecule of
claim 16, wherein said LSST-2 has substantially the amino
acid sequence of SEQ ID NO: 6.

18. The isolated nucleic acid molecule of
15 claim 17, comprising a nucleic acid sequence encoding SEQ
ID NO: 6.

19. The isolated nucleic acid molecule of
claim 18, comprising SEQ ID NO: 5.

20. An isolated polypeptide, comprising an
20 amino acid sequence encoding a LSST-2 or active fragment
thereof, wherein said LSST-2 or active fragment thereof
directs expression of a MECA-79 antigen in CHO cells.

21. The isolated polypeptide of claim 20,
wherein said LSST-2 has substantially the amino acid
25 sequence of SEQ ID NO: 6.

22. The isolated polypeptide of claim 21,
wherein said LSST-2 has the amino acid sequence SEQ ID
NO: 6.

23. An isolated nucleic acid molecule,
5 comprising a nucleic acid sequence encoding substantially
the amino acid sequence of intestinal GlcNAc
6-sulfotransferase (I-GlcNAc6ST) or an active fragment
thereof.

24. The isolated nucleic acid molecule of
10 claim 23, wherein said I-GlcNAc6ST has substantially the
amino acid sequence of SEQ ID NO: 8.

25. The isolated nucleic acid molecule of
claim 24, comprising a nucleic acid sequence encoding SEQ
ID NO: 8.

15 26. The isolated nucleic acid molecule of
claim 25, comprising SEQ ID NO: 7.

27. An isolated polypeptide, comprising an
amino acid sequence encoding substantially the amino acid
sequence of intestinal GlcNAc 6-sulfotransferase
20 (I-GlcNAc6ST) or an active fragment thereof.

28. The isolated polypeptide of claim 27,
wherein said I-GlcNAc6ST has substantially the amino acid
sequence of SEQ ID NO: 8.

29. The isolated polypeptide of claim 28,
25 wherein said I-GlcNAc6ST has the amino acid sequence SEQ
ID NO: 8.




FIG. 1

CTGGCTGGCCAGGATGAAGTATCTCCGGCACCGGCGGCCAATGCCACCCCTCATTCTGGC 60
 M K Y L R H R R P N A T L I L A 16

 CATCGCGCTTCACCCCTCCTCTTCAGTCTGCTAGTGTCAACCACCCACCTGCAAGGT 120
 I G A F T L L L F S L L V S P P T C K V 36

 CCAGGAGCAGCCACCGGCATCCCCGAGGCCCTGGCCTGGCCCACCTCCACCCACCCGCC 180
 Q E Q P P A I P E A L A W P T P P T R P 56

 AGCCCCGGCCCCGTGCCATGCCAACACCTCTATGGTCACCCACCCGGACTTCGCCACGCA 240
 A P A P C H A N T S M V T H P D F A T Q .76

 GCCGCAGCACGTTCAAGAACTTCCTCCTGTACAGACACTGCCGCCACTTCCCTGCTGCA 300
 P Q H V Q N F L L Y R H C R H F P L L Q 96

 GGACGTGCCCTCTAAAGTGCAGCAGCCGGCTTCCCTGCTGGTGATCAAGTCCTC 360
 D V P P S K C A Q P V F L L L V I K S S 116

 CCCTAGCAACTATGTGCAGCCTCTCTGGGGCACAGCCTCCAACCGCACAGGC 420
 P S N Y V R R E L L R R T W G R E R K V 136

 ACGGGGTTTGCAGCTGCCTCTCTGGGGCACAGCCTCCAACCGCACAGGC 480
 R G L Q L R L L F L V G T A S N P H E A 156

 CCGCAAGGTCAACCGGCTGGAGCTGGAGGCACAGACTCACGGAGACATCCTGCAGTG 540
 R K V N R L L E L E A Q T H G D I L Q W 156

 GGACTTCCACGACTCCTCTCAACCTCACGCTCAAGCAGGTCTGTTACAGTGGCA 600
 D F H D S F F N L T L K Q V L F L Q W Q 176

 GGAGACAAGGTGCAGCCTACGGCTGGAGGACTGGAGCAAGTACTATGTGCCAGA 660
 E T R C A N A S F V L N G D D D D V F A H 196

 CACAGACAACATGGTCTTCTACCTGCAGGACCATGACCCTGGCCACCTCTCGTGGG 720
 T D N M V F Y L Q D H D P G R H L F V G 216

 GCAACTGATCCAAAACGTGGGCCCCATCCGGCTTTGGAGCAAGTACTATGTGCCAGA 780
 Q L I Q N V G P I R A F W S K Y Y V P E 236

 GGTGGTGAUTCAGAATGAGCGGTACCCACCCATTGTGGGGGTGGTGGCTTCTGCTGTC 840
 V V T Q N E R Y P P Y C G G G G F L L S 256

 CCGCTTACGGCCGCTGCCCTGCAGCCTGCTGCCATGTCTGGACATCTCCCATGTA 900
 R F T A A A L R R A A H V L D I F P I D 276

 TGATGTCTTCTGGGTATGTGTCTGGAGCTTGAGGGACTGAAGCCTGCCCTCCACAGCGG 960
 D V F L G M C L E L E G L K P A S H S G 296

 CATCCGCACGTCTGGCGTGCAGGCTCCATCGAACACCTGTCTCTCTTGACCCCTGCTT 1020
 I R T S G V R A P S Q H L S S F D P C F 316

 CTACCGAGACCTGCTGGTGCAGGCTTCCATCGAACACCTGTCTCTCTTGACCCCTGCTT 1080
 Y R D L L L V H R F L P Y E M L L M W D 336

FIG. 2
SUBSTITUTE SHEET (RULE 26)

TGCGCTGAACCAGCCCACCTCACCTGGGCAATCAGACACAGATCTACTGAGTCAGCAT 1140
A L N Q P N L T C G N Q T Q I Y * 352

CAGGCATCCGCACGTCTGGCGTGGGGCTCCATCGAACACACCTGTCCTCCTTGACCCCT 1200
GCTTCTAC 1210

FIG. 2 CONT.

AGGCTCCGCCCCACGCCATGCCGGCTGCCAAGGCAGAGCCCCTACGAGATCCTCCTCTG	60
M R L P R Q S P Y E I L L L	14
GTCTTGGTCGCCCTGCTGGTGCTGCTGCTGCTCCTGACCAGCAAGTCACCGCCCAGCTGC	120
V L V A L L V L L L L T S K S P P S C	34
TCCGCCCTGAGAGGTCCAAGGAGCCTGAAGACAACCCGGTGGGCCACGGGCCACCCC	180
S A P E R S K E P E D N P G W A T G H P	54
GCCCCGTGCCAGCTAATCTATCCGTGCTCTCGCACCCGACTTCGCGGGCTGCCCTTG	240
A R C R A N L S V S S H P D F A G L P L	74
CACGTGCGCGACTTCTTGTCTACCGCCACTGCCGCACCTCCAGTGCTCCGAGAGCCG	300
H V R D F L F Y R H C R D F P V L R E P	94
CGGGTTACCAAGTGC CGGGAGCCCGTGTCCCTGCTCGCCATCAAGTCCTCGCCTGCA	360
R V T K C A E P V F L L L A I K S S P A	114
AACTATGGCGCCGCCAGATGCTGCCACGACGTGGCGCGAGAGACGGGTGCGTGGG	420
N Y G R R Q M L R T T W A R E R R V R G	134
GCGCCACTGCGCCGCCCTTCCTTGTGGGCTCAGACCGCGACCCACAACAAGCACCGAAA	480
A P L R R L F L V G S D R D P Q Q A R K	154
TACAACCGACTGCTGGAGCTGGAAGCGCAGAAATACGGCGACATTCTCCAGTGGGATTTC	540
Y N R L L E L E A Q K Y G D I L Q W D F	174
CATGACTCCTCTTTAACCTGACGCTTAAGCAGGTCTTCTGGAGTGGCAGCTAACCC	600
H D S F F N L T L K Q V L F L E W Q L T	194
TACTGTACCAACGCCAGCTCGTGTCAATGGGACGACGATGTGTTCGCACACACGGAC	660
Y C T N A S F V L N G D D D D V F A H T D	214
AACATGGTCACCTACCTGCAGGACCACGGACCCGACCAACACCTCTTCGTGGGCACCTG	720
N M V T Y L Q D H D P D Q H L F V G H L	234
ATCCAGAACGTGGGTCCCACCGGGTGCCTGGAGCAAGTACTTCATCCCCGCTGGTG	780
I Q N V G P I R V P W S K Y F I P A L V	254
ATGGCGGAGGACAGATAACCCGCCACTGTGGTGGCGGGCTCTGCTGTCGCGTTTT	840
M A E D R Y P P Y C G G G G F L L S R F	274
ACCGTGGCCGCCCTACGTCCGCCGCCGCGTCCTCCCCATGTTCCCAATCGACGACGTG	900
T V A A L R R A A R V L P M F P I D D V	294
TTCCCTGGGCATGTGTCGTGCAGCAGCAGGGCTGGCTCCCGGACGCACAGCGGAGTGC	960
F L G M C L Q Q Q G L A P G T H S G V R	314
ACTGCGGGGGTTTCCCCCTAGCCCACGTGTGTCATCCTCGACCCCTGCTTCTACCGC	1020
T A G V F P P S P R V S S F D P C F Y R	334
GACCTGCTCCTCGTGCACCGCTTCTGCCCTCGAGATGCTGCTGATGTGGATGCGCTG	1080
D L L L V H R F L P F E M L L M W D A L	354

FIG. 3

SUBSTITUTE SHEET (RULE 26)

AACCAGCCCCAGCTCCTCTGGGCAGGCAGAGCCCCGCTACTGAGAGGTTGGGGAGT	1140
N Q P Q L L C G R Q S P A Y *	368
TGACATCCCCTAGCTCATGTCCTGCCCTCATCCACGTGCAAAGGGCTGGCTTCAAGGAGAA	1200
GTTCAAAGTGAGGGGCAGAAAGGTGGTCTGAGGAGTTCATAGGCAAACCTCTAAGTAC	1260
GCTTGGAAACCCCTTGGTACTGTTACAGCAGGAACCTGAGTCTAGCCAACCTGAGT	1320
GGCTCTAACGTGGCCGCT	1337

FIG. 3 CONT.

1 TTGGCCAGAAGGGAATAGAAGGCAAACAATAAAACAGCAGCCC ACTCCACCC TTTCTG 60

61 TTTGTTCTTAAAGGTCTTCCACTTCAGCACAAATGCTACTGCCTAAAAAAATGAAGCTCC 120
M K L L

121 TGCTGTTCTGGTTCCCAGATGCCATCTGGCTCTATTCTCACATGTACAGCCACA 180
L F L V S Q M A I L A L F F H M Y S H N

181 ACATCAGCTCCCTGCTATGAAGGCACAGCCCCAGCGCATGCACGTGCTGGTTCTGTCTT 240
I S S L S M K A Q P E R M H V L V L S S

241 CCTGGCGCTCTGGCTCTTCTTTGTGGGGCAGCTTTGGGCAGCACCCAGATGTTTCT 300
W R S G S S F V G Q L F G Q H P D V F Y

301 ACCTGATGGAGCCCGCTGGCACGTGTGGATGACCTCAAGCAGAGCACCGCCTGGATGC 360
L M E P A W H V W M T F K Q S T A W M L

361 TGCACATGGCTGTGGGGATCTGATACGGGCCGTCTTCTTGCGCACATGAGCGTCTTG 420
H M A V R D L I R A V F L C D M S V F D

421 ATGCCTACATGGAACCTGGTCCCCGGAGACAGTCCAGGCCTCTTCAGTGGAGAACAGCC 480
A Y M E P G P R R Q S S L F Q W E N S R

481 GGGCCCTGTGTTCTGCACCTGCCGTGACATCATCCCACAAGATGAAATCATCCCCGGG 540
A L C S A P A C D I I P Q D E I I P R A

541 CTCACTGCAGGCTCTGTGCAGTCACAGCCCTTGAGGTGGTGGAGAACGGCCTGCCGCT 600
H C R L L C S Q Q P F E V V E K A C R S

601 CCTACAGCCACGTGGTCTCAAGGAGGTGCCTCTTCAACCTGCAGTCCCTACCCGC 660
Y S H V V L K E V R F F N L Q S L Y P L

661 TGCTGAAAGACCCCTCCCTCAACCTGCATATCGTCACCTGGTCCGGGACCCCCGGCCG 720
L K D P S L N L H I V H L V R D P R A V

721 TGTTCCGTTCCCGAGAACGCACAAAGGGAGATCTCATGATTGACAGTCGCATTGTGATGG 780
F R S R E R T K G D L M I D S R I V M G

781 GGCAGCATGAGCAAAAACCAAGAAGGAGGACCAACCCTACTATGTGATGCAGGTCACT 840
Q H E Q K L K K E D Q P Y Y V M Q V I C

841 GCCAAAGCCAGCTGGAGATCTACAAGACCATCCAGTCCTGCCAAGGCCCTGCAGGAAC 900
Q S Q L E I Y K T I Q S L P K A L Q E R

FIG. 4

SUBSTITUTE SHEET (RULE 26)

901 GCTACCTGCTTGTGCCTATGAGGACCTGGCTCGAGCCCTGTGGCCAGACTTCCGAA 960
Y L L V R Y E D L A R A P V A Q T S R M

961 TGTATGAATTCGTGGGATTGGAATTCTTCCCCATCTCAGACCTGGGTGCATAACATCA 1020
Y E F V G L E F L P H L Q T W V H N I T

1021 CCCGAGGCCAAGGGCATGGGTGACCACGCTTCCACACAAATGCCAGGGATGCCCTTAATG 1080
R G K G M G D H A F H T N A R D A L N V

1081 TCTCCCAGGCTTGGCGCTGGTCTTGCCCTATGAAAAGGTTCTCGACTTCAGAAAGCCT 1140
S Q A W R W S L P Y E K V S R L Q K A C

1141 GTGGCGATGCCATGAATTGCTGGCTACCGCCACGTCAGATCTGAACAAGAACAGAGAA 1200
G D A M N L L G Y R H V R S E Q E Q R N

1201 ACCTGTTGCTGGATCTTCTGTCTACCTGGACTGTCCCTGAGCAAATCCACTAAGAGGGTT 1260
L L L D L L S T W T V P E Q I H *

1261 GAGAAGGCTTGCTGCCACCTGGTGTCAGCCTCAGTCACTTCTCTGAATGCTCTGAGC 1320

1321 CTTGCCTACATCT 1333

FIG. 4 CONT.

P3GAT-I	-----MASKVSCLYVLSSVQWASALWYL-----	20	100	100
P3GAT-II	-----MLQRARRHCCFAKHTWSPLRSLLRPLTCVLSLVLFAHEFFNNKHDWLPGRPFKENPPVTTFRERSTKSETNHSSSLRTIWKEVAPQTLRPHIASNSS-----	31	31	31
P3GAT-III	-----MAPAVLTALPNRASRSRLKNSLLLSSLSFL-----	39	100	100
P3GAT-IV	-----MPLSLPFRVLLAVLVLVITLFG-----	29	39	39
P3GAT	-----	6	6	6
P3GAT-I	YTGSKP--FSHLTVARKNFTFGNIR-TRPINPHSFSEFILNEPKCEKNIP-----	120	140	160
P3GAT-II	NTESLPGQVTGLQMTLSANGSTYNEKGTHPSYHKTZINEPEKQEKS-----	140	140	140
P3GAT-III	HYMVIERYMMYFYEV--EPIVQDQFRFTLREHNSCNSHNP-----	140	140	140
P3GAT-IV	EELSLSLASLSPAPASPGPPLALPRLTSNSH-ACGGSCPP--FILINACTAEPHLNQRNAFRAWSGATREARG-FRYQTLFLGKPR-----	140	140	140
P3GAT	-----ANHRYVALGGGLAFCGT-TLLYCARCASEGETPSAGAAARPRAKAF-----	140	140	140
P3GAT-I	DPIPQVTECISQIFH-----	220	240	260
P3GAT-II	KLNGLYLQHAIQBSRQYH-----	220	240	260
P3GAT-III	ERDKTTLASLSDHVL-----	220	240	260
P3GAT-IV	RQ---QLAQIASSSAARH-----	220	240	260
P3GAT	LGS---ERRATEEBOAQHEDL-----	220	240	260
P3GAT-I	YPTGTYING-GPTIDVRSKWMMPDOLPQSH-----	320	340	360
P3GAT-II	YPTGTYLARGYAPKNNKOSKWMMPDOLPQSH-----	320	340	360
P3GAT-III	FPTGTYLQGRRLAISFFKAKHSYQEPLPKV-----	320	340	360
P3GAT-IV	RQQAVPLV-----	320	340	360
P3GAT	LGWVHWRVPPTPSRHYSEELPENMGPP-----	320	340	360
P3GAT-I	-----GIVKPG-GRWREALAQLCD-YVLPALGCGMLADLVN-----	420	440	460
P3GAT-II	-----KMSVSKYRPAVITYWQDSEPEYHCLDNNDSSKK-----	420	440	460
P3GAT-III	-----RVSISCKSKYKSHQTSQFOPSELVQHNMHQDNK-----	420	440	460
P3GAT-IV	-----RHDLDYQGRRLAISFFKAKHSYQEPLPKV-----	420	440	460
P3GAT	-----PLDR-COYGFKFLITSKQDWPQDFAWKUNGANGERTA-----	420	440	460
P3GAT-I	-----YKSR-QMNNQKQIATL-WKQPEDNLERQHQLLIGRGLCKIEVQLRLSYWVNSAPSOCCKERGCV-----	480	480	480
P3GAT-II	-----KMSVSKYRPAVITYWQDSEPEYHCLDNNDSSKK-----	480	480	480
P3GAT-III	-----RVSISCKSKYKSHQTSQFOPSELVQHNMHQDNK-----	480	480	480
P3GAT-IV	-----RHDLDYQGRRLAISFFKAKHSYQEPLPKV-----	480	480	480
P3GAT	-----PLDR-COYGFKFLITSKQDWPQDFAWKUNGANGERTA-----	480	480	480

SUBSTITUTE SHEET (RULE 26)

5
FIG.




FIG. 6




FIG. 7




FIG. 8




FIG. 9

TGAGCGGCTTTGTGTGCGCCCTGGGTGCGCAGCGCAGAACGCGCAGCGGGCAGCGCAGG 60
 CCCTAGCCAGAGGTATGCGGCTACCCCGTTCTCCAGCACTGTCATGCTTGCCTCTGA 120
 M R L P R F S S T V M L S L L M
 TGGTACAGACTGGCATCTGGCTTCCCTGGCTCCCAGCAAGTGCCATGCCCCAGCAG 180
 V Q T G I L V F L V S R Q V P S S P A G
 GCCTTGGGGAGCGTGTGCACGTGCTGGTACTGTCCTCGTGGCGCTCGGCTCGTCCCTCG 240
 L G E R V H V L V L S S W R S G S S F V
 TGGGCCAGCTCTCAGCCAACACCCCGATGTCTTACCTGATGGAGCCGGCTGGCACG 300
 G Q L F S Q H P D V F Y L M E P A W H V
 TCTGGGATACTTGTGCGAGGGCAGTGCCCCCGACTCCACATGGCGTGCCTGACCTGA 360
 W D T L S Q G S A P A L H M A V R D L I
 TCCGCTCAGTGTCTATGCGACATGGACGTGGATGCTACCTGCCCTGGGGCCGCA 420
 R S V F L C D M D V F D A Y L P W R R N
 ACATCTGGATCTCTCCAGTGGCGGTGAGCCGCGCATTGTGCTCACCTCCGGTCTGCG 480
 I S D L F Q W A V S R A L C S P P V C E
 AAGCCTTCGCTCGTGGCAACATCAGCAGCGAGGAGGTGTAAAGCCTCTGTGCGAACGC 540
 A F A R G N I S S E E V C K P L C A T R
 GGCCCTCGGCTGGCTCAGGAAGCCTGCAGCTCCTATAGTCACGTCGTGCTCAAGGAGG 600
 P F G L A Q E A C S S Y S H V V L K E V
 TGCGCTTCTTAACCTACAGGTGCTCTACCGCTGCTCAGCGACCCCTGCGCTAACCTGC 660
 R F F N L Q V L Y P L L S D P A L N L R
 GCATCGTGCACCTAGTGCACGCCCCGGCGCTGCTGCCCTCCGAGAGCAGACAGCCA 720
 I V H L V R D P R A V L R S R E Q T A K
 AGGCGCTGGCACGGACAATGGCATGCTCTGGGTACCAACGGCACGTGGTGGAGGCGG 780
 A L A R D N G I V L G T N G T W V E A D
 ACCCCCCGGCTGCGCGTGGTCAACGAGGTATGCCGAGCCATGTGCGCATCGCAGAGGCAG 840
 P R L R V V N E V C R S H V R I A E A A
 CCTTGACAAAGCCGCCCTTCTGCAAGATCGCTACCGCCTGGTGCCTACGAGGATC 900
 L H K P P P F L Q D R Y R L V R Y E D L
 TGGCCCGGGACCCACTCACCGTAATCCGTAACTCTATGCCTCACCGGCTGGGTCTCA 960
 A R D P L T V I R E L Y A F T G L G L T

FIG. 10

CGCCGCAGCTCCAGACTTGGATCCACAATATCACGCATGGTCAGGCCAGGCGCGCGCC	1020
P Q L Q T W I H N I T H G S G P G A R R	
GTGAAGCCTTCAAGACCACATCCAGGGATGCGCTCAGTGTATCCCAGGCCTGGCGCCACA	1080
E A F K T T S R D A L S V S Q A W R H T	
CGCTGCCCTTGCCAAGATTGCCGGTCCAGGAACGTGCGGGGTGCACTGCAGCTGC	1140
L P F A K I R R V Q E L C G G A L Q L L	
TGGGTACCGGCTGTGCATTGGAGCTTGAGCAAAGGGACCTCTCTGGACCTCCTGC	1200
G Y R S V H S E L E Q R D L S L D L L	
TGCCAAGAGGCATGGACAGTTCAAGTGGCATCGTCCACGGAGAACGAAACCGGAATCTT	1260
P R G M D S F K W A S S T E K Q P E S *	
AGAATTTAGTGGAGAGACCCAGCTATAACATTAGGGTCTATTGGAGTATGATAAAGAAG	1320
GGGCTGGAGAACCAAAGCAAGTAGCTGGGAGTGTGAGTGATCTGTCTGTACTAGG	1380
AAAGGATGGAGTCCAAATCCCACATCTCTTCTGCCAGATTGTAGTTCGGTTGGT	1440
CTTTAGGGTTGGATTCCACCAAGTACTATCGAATGGAAAGCAAAGCTGTGCCCACT	1500
TCCTTCAGAGAGGCAGCCAGCCTCTACTAAAGCACTTCTTCGTTGACTCTCTCCC	1560
CTCTTGATCATACCATGCAATCGCAGAGAATGGGTCCCAGGCCTGCTCTGGAGTGC	1620
GAAAGGCGGGCTGTGGCTGGCTCTAAAATCTGTGCACCTGCCTCTGTTGGCTCACC	1680
CAGACCTCTGCTCACTGCCACGCCCTAGTATCTCAGTCATAGACTGGACAGTTAT	1740
GGGCCTGGTCAAGGAGGAAAATGAGACGATGCTCCCTCTGTGATTCTGTGACCTT	1800
CTAGAAGGAATCCAGGCACACACAAACCATACCTGAGGAGGATGGTTTAATGAAT	1860
CTTGATTTGTCTGAGATGAAAGATCTAATTATGAAATAAACATAATGCTGCG	1920
TGATCCAAAAAA 1937	

FIG. 10 CONT.

SEQUENCE LISTING

<110> The Burnham Institute
 Fukuda, Minoru
 Yeh, Jiunn-Chern
 Hiraoka, Nobuyoshi

<120> Identification of the Meca-79 Antigen
 and Related Methods of Treating L-Selectin-Mediated
 Conditions

<130> FP-LJ 4631

<140> PCT/US01/15452

<141> 2001-05-10

<150> US 09/569,320

<151> 2000-05-11

<160> 29

<170> FastSEQ for Windows Version 4.0

<210> 1
 <211> 1208
 <212> DNA
 <213> Homo Sapien

<220>
 <221> CDS
 <222> (14) . . . (1129)

<400> 1
 ctggctggcc agg atg aag tat ctc cgg cac cgg cgg ccc aat gcc acc 49
 Met Lys Tyr Leu Arg His Arg Arg Pro Asn Ala Thr
 1 5 10

ctc att ctg gcc atc ggc gct ttc acc ctc ctc ttc agt ctg cta 97
 Leu Ile Ala Ile Gly Ala Phe Thr Leu Leu Leu Phe Ser Leu Leu
 15 20 25

gtg tca cca ccc acc tgc aag gtc cag gag cag cca ccg gcg atc ccc 145
 Val Ser Pro Pro Thr Cys Lys Val Gln Glu Gln Pro Pro Ala Ile Pro
 30 35 40

gag gcc ctg gcc tgg ccc act cca ccc acc cgc cca gcc ccg gcc ccg 193
 Glu Ala Leu Ala Trp Pro Thr Pro Pro Thr Arg Pro Ala Pro Ala Pro
 45 50 55 60

tgc cat gcc aac acc tct atg gtc acc cac ccg gac ttc gcc acg cag 241
 Cys His Ala Asn Thr Ser Met Val Thr His Pro Asp Phe Ala Thr Gln
 65 70 75

cgc cag cac gtt cag aac ttc ctc ctg tac aga cac tgc cgc cac ttt 289

Pro Gln His Val Gln Asn Phe Leu Leu Tyr Arg His Cys Arg His Phe			
80	85	90	
ccc ctg ctg cag gac gtg ccc ccc tct aag tgc gcg cag ccg gtc ttc			337
Pro Leu Leu Gln Asp Val Pro Pro Ser Lys Cys Ala Gln Pro Val Phe			
95	100	105	
ctg ctg ctg gtg atc aag tcc tcc cct agc aac tat gtg cgc cgc gag			385
Leu Leu Leu Val Ile Lys Ser Ser Pro Ser Asn Tyr Val Arg Arg Glu			
110	115	120	
ctg ctg cgg cgc acg tgg ggc cgc gag cgc aag gta cgg ggt ttg cag			433
Leu Leu Arg Arg Thr Trp Gly Arg Glu Arg Lys Val Arg Gly Leu Gln			
125	130	135	140
ctg cgc ctc ctc ttc ctg gtg ggc aca gcc tcc aac ccg cac gag gcc			481
Leu Arg Leu Leu Phe Leu Val Gly Thr Ala Ser Asn Pro His Glu Ala			
145	150	155	
cgc aag gtc aac cgg ctg ctg gag ctg gag gca cag act cac gga gac			529
Arg Lys Val Asn Arg Ile Leu Glu Leu Glu Ala Gln Thr His Gly Asp			
160	165	170	
atc ctg cag tgg gac ttc cac gac tcc ttc ttc aac ctc acg ctc aag			577
Ile Leu Gln Trp Asp Phe His Asp Ser Phe Phe Asn Leu Thr Leu Lys			
175	180	185	
cag gtc ctg ttc tta cag tgg cag gag aca agg tgc gcc aac gcc agc			625
Gln Val Leu Phe Leu Gln Trp Gln Glu Thr Arg Cys Ala Asn Ala Ser			
190	195	200	
ttc gtg ctc aac ggg gat gat gac gtc ttt gca cac aca gac aac atg			673
Phe Val Leu Asn Gly Asp Asp Asp Val Phe Ala His Thr Asp Asn Met			
205	210	215	220
gtc ttc tac ctg cag gac cat gac cct ggc cgc cac ctc ttc gtg ggg			721
Val Phe Tyr Leu Gln Asp His Asp Pro Gly Arg His Leu Phe Val Gly			
225	230	235	
caa ctg atc caa aac gtg ggc ccc atc cgg gct ttt tgg agc aag tac			769
Gln Leu Ile Gln Asn Val Gly Pro Ile Arg Ala Phe Trp Ser Lys Tyr			
240	245	250	
tat gtg cca gag gtg gtg act cag aat gag cgg tac cca ccc tat tgt			817
Tyr Val Pro Glu Val Val Thr Gln Asn Glu Arg Tyr Pro Pro Tyr Cys			
255	260	265	
ggg ggt ggt ggc ttc ttg ctg tcc cgc ttc acg gcc gct gcc ctg cgc			865
Gly Gly Gly Phe Leu Leu Ser Arg Phe Thr Ala Ala Ala Leu Arg			
270	275	280	
cgt gct gcc cat gtc ttg gac atc ttc ccc att gat gat gtc ttc ctg			913
Arg Ala Ala His Val Leu Asp Ile Phe Pro Ile Asp Asp Val Phe Leu			
285	290	295	300

WO 01/85177

PCT/US01/15452

ggt atg tgt ctg gag ctt gag gga ctg aag cct gcc tcc cac agc ggc 961
Gly Met Cys Leu Glu Leu Glu Gly Leu Lys Pro Ala Ser His Ser Gly
305 310 315

atc cgc acg tct ggc gtg cggtc cca tcg caa cac ctg tcc tcc ttt 1009
Ile Arg Thr Ser Gly Val Arg Ala Pro Ser Gln His Leu Ser Ser Phe
320 325 330

gac ccc tgc ttc tac cga gac ctg ctg gtg cac cgc ttc cta cct 1057
Asp Pro Cys Phe Tyr Arg Asp Leu Leu Leu Val His Arg Phe Leu Pro
335 340 345

tat gag atg ctg ctc atg tgg gat gcg ctg aac cag ccc aac ctc acc 1105
Tyr Glu Met Leu Leu Met Trp Asp Ala Leu Asn Gln Pro Asn Leu Thr
350 355 360

tgc ggc aat cag aca cag atc tac tgagtcatca tcaggcatcc gcacgtctgg 1159
Cys Gly Asn Gln Thr Gln Ile Tyr
365 370

cgtgcgggct ccatcgcaac acctgtcctc ctttgcaccc tgcttctac 1208

<210> 2
<211> 372
<212> PRT
<213> Homo Sapien

<400> 2
Met Lys Tyr Leu Arg His Arg Arg Pro Asn Ala Thr Leu Ile Leu Ala
1 5 10 15
Ile Gly Ala Phe Thr Leu Leu Phe Ser Leu Leu Val Ser Pro Pro
20 25 30
Thr Cys Lys Val Gln Glu Gln Pro Pro Ala Ile Pro Glu Ala Leu Ala
35 40 45
Trp Pro Thr Pro Pro Thr Arg Pro Ala Pro Ala Pro Cys His Ala Asn
50 55 60
Thr Ser Met Val Thr His Pro Asp Phe Ala Thr Gln Pro Gln His Val
65 70 75 80
Gln Asn Phe Leu Leu Tyr Arg His Cys Arg His Phe Pro Leu Leu Gln
85 90 95
Asp Val Pro Pro Ser Lys Cys Ala Gln Pro Val Phe Leu Leu Val
100 105 110
Ile Lys Ser Ser Pro Ser Asn Tyr Val Arg Arg Glu Leu Leu Arg Arg
115 120 125
Thr Trp Gly Arg Glu Arg Lys Val Arg Gly Leu Gln Leu Arg Leu Leu
130 135 140
Phe Leu Val Gly Thr Ala Ser Asn Pro His Glu Ala Arg Lys Val Asn
145 150 155 160
Arg Leu Leu Glu Leu Glu Ala Gln Thr His Gly Asp Ile Leu Gln Trp
165 170 175
Asp Phe His Asp Ser Phe Phe Asn Leu Thr Leu Lys Gln Val Leu Phe
180 185 190
Leu Gln Trp Gln Glu Thr Arg Cys Ala Asn Ala Ser Phe Val Leu Asn
195 200 205
Gly Asp Asp Asp Val Phe Ala His Thr Asp Asn Met Val Phe Tyr Leu

WO 01/85177

PCT/US01/15452

210 215 220
Gln Asp His Asp Pro Gly Arg His Leu Phe Val Gly Gln Leu Ile Gln
225 230 235 240
Asn Val Gly Pro Ile Arg Ala Phe Trp Ser Lys Tyr Tyr Val Pro Glu
245 250 255
Val Val Thr Gln Asn Glu Arg Tyr Pro Pro Tyr Cys Gly Gly Gly
260 265 270
Phe Leu Leu Ser Arg Phe Thr Ala Ala Leu Arg Arg Ala Ala His
275 280 285
Val Leu Asp Ile Phe Pro Ile Asp Asp Val Phe Leu Gly Met Cys Leu
290 295 300
Glu Leu Glu Gly Leu Lys Pro Ala Ser His Ser Gly Ile Arg Thr Ser
305 310 315 320
Gly Val Arg Ala Pro Ser Gln His Leu Ser Ser Phe Asp Pro Cys Phe
325 330 335
Tyr Arg Asp Leu Leu Val His Arg Phe Leu Pro Tyr Glu Met Leu
340 345 350
Leu Met Trp Asp Ala Leu Asn Gln Pro Asn Leu Thr Cys Gly Asn Gln
355 360 365
Thr Gln Ile Tyr
370

<210> 3
<211> 1337
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (19) ... (1122)

<400> 3
aggctccgcc cccacgccc atg cgg ctg cca agg cag agc ccc tac gag atc 51
Met Arg Leu Pro Arg Gln Ser Pro Tyr Glu Ile
1 5 10

ctc ctc ctg gtc ttg gtc gcc ttg ctg gtg ctg ctg ctc ctg acc 99
Leu Leu Leu Val Leu Val Ala Leu Leu Val Leu Leu Leu Leu Leu Thr
15 20 25

agc aag tca ccg ccc agc tgc tcc gcc cct gag agg tcc aag gag cct 147
Ser Lys Ser Pro Pro Ser Cys Ser Ala Pro Glu Arg Ser Lys Glu Pro
30 35 40

gaa gac aac ccc ggg tgg gcc acg ggc cac ccc gcc cgg tgc cga gct 195
Glu Asp Asn Pro Gly Trp Ala Thr Gly His Pro Ala Arg Cys Arg Ala
45 50 55

aat cta tcc gtg tcc tcc cac ccc gac ttc gcg ggg ctg ccc ttg cac 243
Asn Leu Ser Val Ser Ser His Pro Asp Phe Ala Gly Leu Pro Leu His
60 65 70 75

gtg cgc gac ttc ttg ttc tac cgc cac tgc cgc gac ttc cca gtg ctc 291
Val Arg Asp Phe Leu Phe Tyr Arg His Cys Arg Asp Phe Pro Val Leu

80	85	90	
cga gag ccg cgg gtt acc aag tgc gcg gag ccc gtg ttc ctg ctg ctc Arg Glu Pro Arg Val Thr Lys Cys Ala Glu Pro Val Phe Leu Leu Leu 95	100	105	339
gcc atc aag tcc tcg cct gca aac tat ggg cgc cgc cag atg ctg cgc Ala Ile Lys Ser Ser Pro Ala Asn Tyr Gly Arg Arg Gln Met Leu Arg 110 115 120			387
acg acg tgg gcg cgc gag aga cgg gtg cgt ggg gcg cca ctg cgc cgc Thr Thr Trp Ala Arg Glu Arg Arg Val Arg Gly Ala Pro Leu Arg Arg 125 130 135			435
ctc ttc ctt gtg ggc tca gac cgc gac cca caa gca cgc aaa tac Leu Phe Leu Val Gly Ser Asp Arg Asp Pro Gln Gln Ala Arg Lys Tyr 140 145 150 155			483
aac cga ctg ctg gag ctg gaa gcg cag aaa tac ggc gac att ctc cag Asn Arg Leu Leu Glu Leu Glu Ala Gln Lys Tyr Gly Asp Ile Leu Gln 160 165 170			531
tgg gat ttc cat gac tcc ttc ttt aac ctg acg ctt aag cag gtc ctt Trp Asp Phe His Asp Ser Phe Phe Asn Leu Thr Leu Lys Gln Val Leu 175 180 185			579
ttc ctg gag tgg cag cta acc tac tgt acc aac gcc agc ttc gtg ctc Phe Leu Glu Trp Gln Leu Thr Tyr Cys Thr Asn Ala Ser Phe Val Leu 190 195 200			627
aat ggg gac gac gat gtg ttc gca cac acg gac aac atg gtc acc tac Asn Gly Asp Asp Asp Val Phe Ala His Thr Asp Asn Met Val Thr Tyr 205 210 215			675
ctg cag gac cac gac ccg gac caa cac ctc ttc gtg ggg cac ctg atc Leu Gln Asp His Asp Pro Asp Gln His Leu Phe Val Gly His Leu Ile 220 225 230 235			723
cag aac gtg ggt ccc atc cgg gtg ccc tgg agc aag tac ttc atc ccc Gln Asn Val Gly Pro Ile Arg Val Pro Trp Ser Lys Tyr Phe Ile Pro 240 245 250			771
gct ctg gtg atg gcg gag gac aga tac ccg ccc tac tgt ggt ggc ggc Ala Leu Val Met Ala Glu Asp Arg Tyr Pro Pro Tyr Cys Gly Gly 255 260 265			819
ggc ttc ctg ctg tcg cgt ttt acc gtg gcc gcc cta cgt cgc gcc gcg Gly Phe Leu Leu Ser Arg Phe Thr Val Ala Ala Leu Arg Arg Ala Ala 270 275 280			867
cgc gtc ctc ccc atg ttc cca atc gac gac gtg ttc ctg ggc atg tgt Arg Val Leu Pro Met Phe Pro Ile Asp Asp Val Phe Leu Gly Met Cys 285 290 295			915
ctg cag cag cag ggt ctg gct ccc ggg acg cac agc gga gtg cgc act			963

WO 01/85177

PCT/US01/15452

Leu Gln Gln Gln Gly Leu Ala Pro Gly Thr His Ser Gly Val Arg Thr
300 305 310 315

gct ggg gtt ttc ccc cct agc cca cgt gtg tca tcc ttc gac ccc tgc 1011
Ala Gly Val Phe Pro Pro Ser Pro Arg Val Ser Ser Phe Asp Pro Cys
320 325 330

tcc tac cgc gac ctg ctc ctc gtg cac cgc ttc ctg ccc ttc gag atg 1059
Phe Tyr Arg Asp Leu Leu Leu Val His Arg Phe Leu Pro Phe Glu Met
335 340 345

ctg ctg atg tgg gat gct gctg aac cag ccc cag ctc ctc tgc ggc agg 1107
Leu Leu Met Trp Asp Ala Leu Asn Gln Pro Gln Leu Leu Cys Gly Arg
350 355 360

cag aqc ccc gcc tac tgagaggttt gggggagttt acatccccata gtcgtatgtcc 1162
Gln Ser Pro Ala Tyr
365

tgcctcatcc acgtgcaaag ggctggcttc aaggagaagt tcaaagttag gggcagaaag 1222
gtgggtctga ggagtcata gggcaaactc ctaagtacgc ttggaaaccc tcttggtact 1282
gttcacagca ggaactctga gtctagccaa ctctgagtgg ctctaagtgg ccgct 1337

<210> 4
<211> 368
<212> PRT
<213> Mus musculus

<400> 4
Met Arg Leu Pro Arg Gln Ser Pro Tyr Glu Ile Leu Leu Leu Val Leu
1 5 10 15
Val Ala Leu Leu Val Leu Leu Leu Leu Thr Ser Lys Ser Pro Pro
20 25 30
Ser Cys Ser Ala Pro Glu Arg Ser Lys Glu Pro Glu Asp Asn Pro Gly
35 40 45
Trp Ala Thr Gly His Pro Ala Arg Cys Arg Ala Asn Leu Ser Val Ser
50 55 60
Ser His Pro Asp Phe Ala Gly Leu Pro Leu His Val Arg Asp Phe Leu
65 70 75 80
Phe Tyr Arg His Cys Arg Asp Phe Pro Val Leu Arg Glu Pro Arg Val
85 90 95
Thr Lys Cys Ala Glu Pro Val Phe Leu Leu Ala Ile Lys Ser Ser
100 105 110
Pro Ala Asn Tyr Gly Arg Arg Gln Met Leu Arg Thr Thr Trp Ala Arg
115 120 125
Glu Arg Arg Val Arg Gly Ala Pro Leu Arg Arg Leu Phe Leu Val Gly
130 135 140
Ser Asp Arg Asp Pro Gln Ala Arg Lys Tyr Asn Arg Leu Leu Glu
145 150 155 160
Leu Glu Ala Gln Lys Tyr Gly Asp Ile Leu Gln Trp Asp Phe His Asp
165 170 175
Ser Phe Phe Asn Leu Thr Leu Lys Gln Val Leu Phe Leu Glu Trp Gln
180 185 190
Leu Thr Tyr Cys Thr Asn Ala Ser Phe Val Leu Asn Gly Asp Asp Asp
195 200 205

Val Phe Ala His Thr Asp Asn Met Val Thr Tyr Leu Gln Asp His Asp
 210 215 220
 Pro Asp Gln His Leu Phe Val Gly His Leu Ile Gln Asn Val Gly Pro
 225 230 235 240
 Ile Arg Val Pro Trp Ser Lys Tyr Phe Ile Pro Ala Leu Val Met Ala
 245 250 255
 Glu Asp Arg Tyr Pro Pro Tyr Cys Gly Gly Gly Phe Leu Leu Ser
 260 265 270
 Arg Phe Thr Val Ala Ala Leu Arg Arg Ala Ala Arg Val Leu Pro Met
 275 280 285
 Phe Pro Ile Asp Asp Val Phe Leu Gly Met Cys Leu Gln Gln Gly
 290 295 300
 Leu Ala Pro Gly Thr His Ser Gly Val Arg Thr Ala Gly Val Phe Pro
 305 310 315 320
 Pro Ser Pro Arg Val Ser Ser Phe Asp Pro Cys Phe Tyr Arg Asp Leu
 325 330 335
 Leu Leu Val His Arg Phe Leu Pro Phe Glu Met Leu Leu Met Trp Asp
 340 345 350
 Ala Leu Asn Gln Pro Gln Leu Leu Cys Gly Arg Gln Ser Pro Ala Tyr
 355 360 365

<210> 5
<211> 1333
<212> DNA
<213> Homo Sapien

<220>
<221> CDS
<222> (111) . . . (1250)

<400> 5
ttggccagaa gggaaataga aggcaaacaa taaaacagca gcccaactcc accctttctg 60
tttgttcctt aaaggcttcc cacttcagca caatgctact gcctaaaaaa atg aag 116
Met Lys
1
ctc ctg ctg ttt ctg gtt tcc cag atg gcc atc ttg gct cta ttc ttc 164
Leu Leu Leu Phe Leu Val Ser Gln Met Ala Ile Leu Ala Leu Phe Phe
5 10 15
cac atg tac agc cac aac atc agc tcc ctg tct atg aag gca cag ccc 212
His Met Tyr Ser His Asn Ile Ser Ser Leu Ser Met Lys Ala Gln Pro
20 25 30
gag cgc atg cac gtg ctg gtt ctg tct tcc tgg cgc tct ggc tct tct 260
Glu Arg Met His Val Leu Val Leu Ser Ser Trp Arg Ser Gly Ser Ser
35 40 45 50
ttt gtg ggg cag ctt ttt ggg cag cac cca gat gtt ttc tac ctg atg 308
Phe Val Gly Gln Leu Phe Gly Gln His Pro Asp Val Phe Tyr Leu Met
55 60 65
gag ccc gcc tgg cac gtg tgg atg acc ttc aag cag agc acc gcc tgg 356
Glu Pro Ala Trp His Val Trp Met Thr Phe Lys Gln Ser Thr Ala Trp

70	75	80	
atg ctg cac atg gct gtg cgg gat ctg ata cgg gcc gtc ttc ttg tgc Met Leu His Met Ala Val Arg Asp Ile Arg Ala Val Phe Leu Cys	85	90	404
95			
gac atg agc gtc ttt gat gcc tac atg gaa cct ggt ccc cgg aga cag Asp Met Ser Val Phe Asp Ala Tyr Met Glu Pro Gly Pro Arg Arg Gln	100	105	452
110			
tcc agc ctc ttt cag tgg gag aac agc cgg gcc ctg tgt tct gca cct Ser Ser Leu Phe Gln Trp Glu Asn Ser Arg Ala Leu Cys Ser Ala Pro	115	120	500
125			
130			
gcc tgt gac atc atc cca caa gat gaa atc atc ccc cgg gct cac tgc Ala Cys Asp Ile Ile Pro Gln Asp Glu Ile Ile Pro Arg Ala His Cys	135	140	548
145			
agg ctc ctg tgc agt caa cag ccc ttt gag gtg gtg gag aag gcc tgc Arg Leu Leu Cys Ser Gln Gln Pro Phe Glu Val Val Glu Lys Ala Cys	150	155	596
160			
cgc tcc tac agc cac gtg gtg ctc aag gag gtg cgc ttc ttc aac ctg Arg Ser Tyr Ser His Val Val Leu Lys Glu Val Arg Phe Phe Asn Leu	165	170	644
175			
cag tcc ctc tac ccg ctg ctg aaa gac ccc tcc ctc aac ctg cat atc Gln Ser Leu Tyr Pro Leu Leu Lys Asp Pro Ser Leu Asn Leu His Ile	180	185	692
190			
gtg cac ctg gtc cgg gac ccc cgg gcc gtg ttc cgt tcc cga gaa cgc Val His Leu Val Arg Asp Pro Arg Ala Val Phe Arg Ser Arg Glu Arg	195	200	740
205			
210			
aca aag gga gat ctc atg att gac agt cgc att gtg atg ggg cag cat Thr Lys Gly Asp Ieu Met Ile Asp Ser Arg Ile Val Met Gly Gln His	215	220	788
225			
gag caa aaa ctc aag aag gag gac caa ccc tac tat gtg atg cag gtc Glu Gln Lys Leu Lys Lys Glu Asp Gln Pro Tyr Tyr Val Met Gln Val	230	235	836
240			
atc tgc caa agc cag ctg gag atc tac aag acc atc cag tcc ttg ccc Ile Cys Gln Ser Gln Leu Glu Ile Tyr Lys Thr Ile Gln Ser Leu Pro	245	250	884
255			
aag gcc ctg cag gaa cgc tac ctg ctt gtg cgc tat gag gac ctg gct Lys Ala Leu Gln Glu Arg Tyr Leu Leu Val Arg Tyr Glu Asp Leu Ala	260	265	932
270			
cga gcc cct gtg gcc cag act tcc cga atg tat gaa ttc gtg gga ttg Arg Ala Pro Val Ala Gln Thr Ser Arg Met Tyr Glu Phe Val Gly Leu	275	280	980
285			
290			
gaa ttc ttg ccc cat ctt cag acc tgg gtg cat aac atc acc cga ggc			1028

WO 01/85177

PCT/US01/15452

Glu Phe Leu Pro His Leu Gln Thr Trp Val His Asn Ile Thr Arg Gly
295 300 305

aag ggc atg ggt gac cac gct ttc cac aca aat gcc agg gat gcc ctt 1076
Lys Gly Met Gly Asp His Ala Phe His Thr Asn Ala Arg Asp Ala Leu
310 315 320

aat gtc tcc cag gct tgg cgc tgg tct ttg ccc tat gaa aag gtt tct 1124
Asn Val Ser Gln Ala Trp Arg Trp Ser Leu Pro Tyr Glu Lys Val Ser
325 330 335

cga ctt cag aaa gcc tgt ggc gat gcc atg aat ttg ctg ggc tac cgc 1172
Arg Leu Gln Lys Ala Cys Gly Asp Ala Met Asn Leu Leu Gly Tyr Arg
340 345 350

cac gtc aga tct gaa caa gaa cag aga aac ctg ttg ctg gat ctt ctg 1220
His Val Arg Ser Glu Gln Glu Gln Arg Asn Leu Leu Asp Leu Leu
355 360 365 370

tct acc tgg act gtc cct gag caa atc cac taagagggtt gagaaggctt 1270
Ser Thr Trp Thr Val Pro Glu Gln Ile His
375 380

tgctgccacc tggtgtcagc ctcagtcact ttctctgaat gcttctgagc cttgcctaca 1330
tct 1333

<210> 6
<211> 380
<212> PRT
<213> Homo Sapien

<400> 6
Met Lys Leu Leu Leu Phe Leu Val Ser Gln Met Ala Ile Leu Ala Leu
1 5 10 15
Phe Phe His Met Tyr Ser His Asn Ile Ser Ser Leu Ser Met Lys Ala
20 25 30
Gln Pro Glu Arg Met His Val Leu Val Leu Ser Ser Trp Arg Ser Gly
35 40 45
Ser Ser Phe Val Gly Gln Leu Phe Gly Gln His Pro Asp Val Phe Tyr
50 55 60
Leu Met Glu Pro Ala Trp His Val Trp Met Thr Phe Lys Gln Ser Thr
65 70 75 80
Ala Trp Met Leu His Met Ala Val Arg Asp Leu Ile Arg Ala Val Phe
85 90 95
Leu Cys Asp Met Ser Val Phe Asp Ala Tyr Met Glu Pro Gly Pro Arg
100 105 110
Arg Gln Ser Ser Leu Phe Gln Trp Glu Asn Ser Arg Ala Leu Cys Ser
115 120 125
Ala Pro Ala Cys Asp Ile Ile Pro Gln Asp Glu Ile Ile Pro Arg Ala
130 135 140
His Cys Arg Leu Leu Cys Ser Gln Gln Pro Phe Glu Val Val Glu Lys
145 150 155 160
Ala Cys Arg Ser Tyr Ser His Val Val Leu Lys Glu Val Arg Phe Phe
165 170 175
Asn Leu Gln Ser Leu Tyr Pro Leu Leu Lys Asp Pro Ser Leu Asn Leu

180	185	190
His Ile Val His Leu Val Arg Asp Pro Arg Ala Val Phe Arg Ser Arg		
195	200	205
Glu Arg Thr Lys Gly Asp Leu Met Ile Asp Ser Arg Ile Val Met Gly		
210	215	220
Gln His Glu Gln Lys Leu Lys Glu Asp Gln Pro Tyr Tyr Val Met		
225	230	235
Gln Val Ile Cys Gln Ser Gln Leu Glu Ile Tyr Lys Thr Ile Gln Ser		
245	250	255
Leu Pro Lys Ala Leu Gln Glu Arg Tyr Leu Leu Val Arg Tyr Glu Asp		
260	265	270
Leu Ala Arg Ala Pro Val Ala Gln Thr Ser Arg Met Tyr Glu Phe Val		
275	280	285
Gly Leu Glu Phe Leu Pro His Leu Gln Thr Trp Val His Asn Ile Thr		
290	295	300
Arg Gly Lys Gly Met Gly Asp His Ala Phe His Thr Asn Ala Arg Asp		
305	310	315
Ala Leu Asn Val Ser Gln Ala Trp Arg Trp Ser Leu Pro Tyr Glu Lys		
325	330	335
Val Ser Arg Leu Gln Lys Ala Cys Gly Asp Ala Met Asn Leu Leu Gly		
340	345	350
Tyr Arg His Val Arg Ser Glu Gln Glu Gln Arg Asn Leu Leu Leu Asp		
355	360	365
Leu Leu Ser Thr Trp Thr Val Pro Glu Gln Ile His		
370	375	380

<210> 7
<211> 1937
<212> DNA
<213> Mus musculus

<220>
<221> CDS
<222> (75) ... (1259)

<400> 7		
tgagcggctc tttgtgtgcg ccctgggtgc gcagcgacaga agcgcagcgg gcagcgccagg	60	
ccctagccag aggt atg cgg cta ccc cgt ttc tcc agc act gtc atg ctt	110	
Met Arg Leu Pro Arg Phe Ser Ser Thr Val Met Leu		
1	5	10
tcg ctc ctg atg gta cag act ggc atc ctg gtc ttc ctg gtc tcc cgg	158	
Ser Leu Leu Met Val Gln Thr Gly Ile Leu Val Phe Leu Val Ser Arg		
15	20	25
caa gtg cca tcg tcc cca gca ggc ctt ggg gag cgt gtg cac gtg ctg	206	
Gln Val Pro Ser Ser Pro Ala Gly Leu Gly Glu Arg Val His Val Leu		
30	35	40
gta ctg tcc tcg tgg cgc tcg ggc tcc ttc gtg ggc cag ctc ttc	254	
Val Leu Ser Ser Trp Arg Ser Gly Ser Ser Phe Val Gly Gln Leu Phe		
45	50	55
agc caa cac ccc gat gtc ttc tac ctg atg gag ccg gct tgg cac gtc	302	

WO 01/85177

PCT/US01/15452

Ser Gln His Pro Asp Val Phe Tyr Leu Met Glu Pro Ala Trp His Val		
65	70	75
tgg gat acg ttg tcg cag ggc agt gcc ccc gca ctc cac atg gcc gtg Trp Asp Thr Leu Ser Gln Gly Ser Ala Pro Ala Leu His Met Ala Val		
80	85	90
cgt gac ctg atc cgc tca gtg ttc cta tgc gac atg gac gta ttt gat Arg Asp Leu Ile Arg Ser Val Phe Leu Cys Asp Met Asp Val Phe Asp		
95	100	105
gcc tac ctg ccc tgg cgc cgc aac atc tcg gat ctc ttc cag tgg gcg Ala Tyr Leu Pro Trp Arg Arg Asn Ile Ser Asp Leu Phe Gln Trp Ala		
110	115	120
gtg agc cgc gca ttg tgc tca cct ccg gtc tgc gaa gcc ttc gct cgt Val Ser Arg Ala Leu Cys Ser Pro Pro Val Cys Glu Ala Phe Ala Arg		
125	130	135
ggc aac atc agc agc gag gag gtg tgt aag cct ctg tgc gca acg cgg Gly Asn Ile Ser Ser Glu Glu Val Cys Lys Pro Leu Cys Ala Thr Arg		
145	150	155
ccc ttc ggc ctg gct cag gaa gcc tgc agc tcc tat agt cac gtc gtg Pro Phe Gly Leu Ala Gln Glu Ala Cys Ser Ser Tyr Ser His Val Val		
160	165	170
ctc aag gag gtg cgc ttc ttt aac cta cag gtg ctc tac ccg ctg ctc Leu Lys Glu Val Arg Phe Phe Asn Leu Gln Val Leu Tyr Pro Leu Leu		
175	180	185
agc gac cct gcg ctc aac ctg cgc atc gtg cac cta gtg cgc gac ccg Ser Asp Pro Ala Leu Asn Leu Arg Ile Val His Leu Val Arg Asp Pro		
190	195	200
cgg gcc gtg ctg cgc tcc cga gag cag aca gcc aag gcg ctg gca cgg Arg Ala Val Leu Arg Ser Arg Glu Gln Thr Ala Lys Ala Leu Ala Arg		
205	210	215
gac aat ggc atc gtc ctg ggt acc aac ggc acg tgg gtg gag gcg gac Asp Asn Gly Ile Val Leu Gly Thr Asn Gly Thr Trp Val Glu Ala Asp		
225	230	235
ccc cgg ctg cgc gtg gtc aac gag gta tgc cgc agc cat gtg cgc atc Pro Arg Leu Arg Val Val Asn Glu Val Cys Arg Ser His Val Arg Ile		
240	245	250
gca gag gca gcc ttg cac aag ccg ccg ccc ttc ttg caa gat cgc tac Ala Glu Ala Ala Leu His Lys Pro Pro Phe Leu Gln Asp Arg Tyr		
255	260	265
cgc ctg gtg cgc tac gag gat ctg gcc cgg gac cca ctc acc gta atc Arg Leu Val Arg Tyr Glu Asp Leu Ala Arg Asp Pro Leu Thr Val Ile		
270	275	280

WO 01/85177

PCT/US01/15452

cgt gaa ctc tat gcc ttc acc ggc ctg ggt ctc acg ccg cag ctc cag Arg Glu Leu Tyr Ala Phe Thr Gly Leu Gly Leu Thr Pro Gln Leu Gln 285	290	295	300	974
act tgg atc cac aat atc acg cat ggt tca ggg cca ggc gcg cgc cgt Thr Trp Ile His Asn Ile Thr His Gly Ser Gly Pro Gly Ala Arg Arg 305	310	315		1022
gaa gcc ttc aag acc aca tcc agg gat gcg ctc agt gta tcc cag gcc Glu Ala Phe Lys Thr Thr Ser Arg Asp Ala Leu Ser Val Ser Gln Ala 320	325	330		1070
tgg cgc cac acg ctg ccc ttt gcc aag att cgc cgg gtc cag gaa ctg Trp Arg His Thr Leu Pro Phe Ala Lys Ile Arg Arg Val Gln Glu Leu 335	340	345		1118
tgc ggg ggt gca ctg cag ctg ctg ggt tac cgg tct gtg cat tcg gag Cys Gly Gly Ala Leu Gln Leu Leu Gly Tyr Arg Ser Val His Ser Glu 350	355	360		1166
ctt gag caa agg gac ctc tct ctg gac ctc ctg cca aga ggc atg Leu Glu Gln Arg Asp Leu Ser Leu Asp Leu Leu Pro Arg Gly Met 365	370	375	380	1214
gac agt ttc aag tgg gca tcc acg gag aag caa ccg gaa tct Asp Ser Phe Lys Trp Ala Ser Ser Thr Glu Lys Gln Pro Glu Ser 385	390	395		1259
tagaaattta gtggagagac ccagctataa cattagggtc tattggagta tgataaagaa 1319 ggggcttggaa gaacccaaaa gcaagttagct gggagtgtga gtgatcttgt cctgtactag 1379 gaaaggatgg agtccaaatc ccacatotct ttctgtccag attgttagttt tcggttttgg 1439 tcttttaggg ttggattcc caccaagtac tatacgatgg aaagccaaag ctgtgcaccac 1499 tcttcattcaga gaggcagcca gccttcataact aaagcacttc ctttcctcggt gactcttc 1559 ctcttttgat cataccatgc attcgcagag aatgggggtc caggectgtct ctggagtgcg 1619 ggaaaggcgc ggctgtgggc tggctctaa aatctgtgc cctgccttc gttggctcac 1679 ccagacctct gtcactgcc acgcctctatc atctcgtcc atcatagact tggacagat 1739 tggccctgtt caaggaggaa aatgagacga tgctccctc tggattctc tgcctgac 1799 tctagaaggg aatccaggca cacacacaac cataacctgag gaggatggct ttttaatgaa 1859 tctttgattt gtccctgagat gaaagatcct aatttatgga aataaacata aatatgctgc 1919 gtgatccaaa aaaaaaaaaa 1937				

<210> 8
<211> 395
<212> PRT
<213> Mus musculus

```

<400> 8
Met Arg Leu Pro Arg Phe Ser Ser Thr Val Met Leu Ser Leu Leu Met
      1           5           10          15
Val Gln Thr Gly Ile Leu Val Phe Leu Val Ser Arg Gln Val Pro Ser
      20          25          30
Ser Pro Ala Gly Leu Gly Glu Arg Val His Val Leu Val Leu Ser Ser
      35          40          45
Trp Arg Ser Gly Ser Ser Phe Val Gly Gln Leu Phe Ser Gln His Pro
      50          55          60

```

WO 01/85177

PCT/US01/15452

Asp Val Phe Tyr Leu Met Glu Pro Ala Trp His Val Trp Asp Thr Leu
65 70 75 80
Ser Gln Gly Ser Ala Pro Ala Leu His Met Ala Val Arg Asp Leu Ile
85 90 95
Arg Ser Val Phe Leu Cys Asp Met Asp Val Phe Asp Ala Tyr Leu Pro
100 105 110
Trp Arg Arg Asn Ile Ser Asp Leu Phe Gln Trp Ala Val Ser Arg Ala
115 120 125
Leu Cys Ser Pro Pro Val Cys Glu Ala Phe Ala Arg Gly Asn Ile Ser
130 135 140
Ser Glu Glu Val Cys Lys Pro Leu Cys Ala Thr Arg Pro Phe Gly Leu
145 150 155 160
Ala Gln Glu Ala Cys Ser Ser Tyr Ser His Val Val Leu Lys Glu Val
165 170 175
Arg Phe Phe Asn Leu Gln Val Leu Tyr Pro Leu Leu Ser Asp Pro Ala
180 185 190
Leu Asn Leu Arg Ile Val His Leu Val Arg Asp Pro Arg Ala Val Leu
195 200 205
Arg Ser Arg Glu Gln Thr Ala Lys Ala Leu Ala Arg Asp Asn Gly Ile
210 215 220
Val Leu Gly Thr Asn Gly Thr Trp Val Glu Ala Asp Pro Arg Leu Arg
225 230 235 240
Val Val Asn Glu Val Cys Arg Ser His Val Arg Ile Ala Glu Ala Ala
245 250 255
Leu His Lys Pro Pro Pro Phe Leu Gln Asp Arg Tyr Arg Leu Val Arg
260 265 270
Tyr Glu Asp Leu Ala Arg Asp Pro Leu Thr Val Ile Arg Glu Leu Tyr
275 280 285
Ala Phe Thr Gly Leu Gly Leu Thr Pro Gln Leu Gln Thr Trp Ile His
290 295 300
Asn Ile Thr His Gly Ser Gly Pro Gly Ala Arg Arg Glu Ala Phe Lys
305 310 315 320
Thr Thr Ser Arg Asp Ala Leu Ser Val Ser Gln Ala Trp Arg His Thr
325 330 335
Leu Pro Phe Ala Lys Ile Arg Arg Val Gln Glu Leu Cys Gly Gly Ala
340 345 350
Leu Gln Leu Leu Gly Tyr Arg Ser Val His Ser Glu Leu Glu Gln Arg
355 360 365
Asp Leu Ser Leu Asp Leu Leu Pro Arg Gly Met Asp Ser Phe Lys
370 375 380
Trp Ala Ser Ser Thr Glu Lys Gln Pro Glu Ser
385 390 395

<210> 9
<211> 26
<212> DNA
<213> Homo Sapien

<400> 9
ctggctggcc aggatgaagt atctcc

26

<210> 10
<211> 28
<212> DNA

WO 01/85177

PCT/US01/15452

<213> Homo Sapien

<400> 10

cctgatgtcg actcagtaga tctgtgtc

28

<210> 11

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 11

cgggatcccg aggccctggc ctggcccact cc

32

<210> 12

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic Construct

<400> 12

gctctagact cagtagatct gtgtctgatt gc

32

<210> 13

<211> 24

<212> DNA

<213> Homo sapien

<400> 13

tccctgtgc tggtgatcaa gtcc

24

<210> 14

<211> 25

<212> DNA

<213> Homo sapien

<400> 14

caggacctgc ttgagcgtga ggttg

25

<210> 15

<211> 29

<212> DNA

<213> Mus musculus

<400> 15

atggaaatcc cactggagaa tgtcgcgt

29

<210> 16

<211> 27

<212> DNA

<213> Mus musculus

<400> 16
gcctgcaaac tatggcgcc gccagat 27

<210> 17
<211> 26
<212> DNA
<213> Homo sapien

<400> 17
ccgaattctc ccgagaacgc acaaag 26

<210> 18
<211> 27
<212> DNA
<213> Homo sapien

<400> 18
cccaagcttc tcatagcgca caagcag 27

<210> 19
<211> 19
<212> DNA
<213> Homo sapien

<400> 19
ttggccagaa gggaaatag 19

<210> 20
<211> 22
<212> DNA
<213> Homo sapien

<400> 20
ccactgaaag aggctggact gt 22

<210> 21
<211> 21
<212> DNA
<213> Homo sapien

<400> 21
gtttctgtct tcctggcgct c 21

<210> 22
<211> 22
<212> DNA
<213> Homo sapien

<400> 22
tttggcagat gacctgcatac ac 22

<210> 23
<211> 22
<212> DNA

WO 01/85177

PCT/US01/15452

<213> Homo sapien

<400> 23

agaacgcaca aaggagatct ca

22

<210> 24

<211> 22

<212> DNA

<213> Homo sapien

<400> 24

agatgttaggc aaggctcaga ag

22

<210> 25

<211> 326

<212> PRT

<213> Mus musculus

<400> 25

Met Ala Ser Lys Val Ser Cys Leu Tyr Val Leu Ser Val Val Cys Trp
1 5 10 15
Ala Ser Ala Leu Trp Tyr Leu Ser Ile Thr Arg Pro Thr Ser Ser Tyr
20 25 30
Thr Gly Ser Lys Pro Phe Ser His Leu Thr Val Ala Arg Lys Asn Phe
35 40 45
Thr Phe Gly Asn Ile Arg Thr Arg Pro Ile Asn Pro His Ser Phe Glu
50 55 60
Phe Leu Ile Asn Glu Pro Asn Lys Cys Glu Lys Asn Ile Pro Phe Leu
65 70 75 80
Val Ile Leu Ile Ser Thr Thr His Lys Glu Phe Asp Ala Arg Gln Ala
85 90 95
Ile Arg Glu Thr Trp Gly Asp Glu Asn Asn Phe Lys Gly Ile Lys Ile
100 105 110
Ala Thr Leu Phe Leu Leu Gly Lys Asn Ala Asp Pro Val Leu Asn Gln
115 120 125
Met Val Glu Gln Glu Ser Gln Ile Phe His Asp Ile Ile Val Glu Asp
130 135 140
Phe Ile Asp Ser Tyr His Asn Leu Thr Leu Lys Thr Leu Met Gly Met
145 150 155 160
Arg Trp Val Ala Thr Phe Cys Ser Lys Ala Lys Tyr Val Met Lys Thr
165 170 175
Asp Ser Asp Ile Phe Val Asn Met Asp Asn Leu Ile Tyr Lys Leu Leu
180 185 190
Lys Pro Ser Thr Lys Pro Arg Arg Tyr Phe Thr Gly Tyr Val Ile
195 200 205
Asn Gly Gly Pro Ile Arg Asp Val Arg Ser Lys Trp Tyr Met Pro Arg
210 215 220
Asp Leu Tyr Pro Asp Ser Asn Tyr Pro Pro Phe Cys Ser Gly Thr Gly
225 230 235 240
Tyr Ile Phe Ser Ala Asp Val Ala Glu Leu Ile Tyr Lys Thr Ser Leu
245 250 255
His Thr Arg Leu Leu His Leu Glu Asp Val Tyr Val Gly Leu Cys Leu
260 265 270
Arg Lys Leu Gly Ile His Pro Phe Gln Asn Ser Gly Phe Asn His Trp
275 280 285

Lys Met Ala Tyr Ser Leu Cys Arg Tyr Arg Arg Val Ile Thr Val His
 290 295 300
 Gln Ile Ser Pro Glu Glu Met His Arg Ile Trp Asn Asp Met Ser Ser
 305 310 315 320
 Lys Lys His Leu Arg Cys
 325

<210> 26
<211> 422
<212> PRT
<213> Mus musculus

<400> 26

Met Leu Gln Trp Arg Arg Arg His Cys Cys Phe Ala Lys Met Thr Trp
 1 5 10 15
 Ser Pro Lys Arg Ser Leu Leu Arg Thr Pro Leu Thr Gly Val Leu Ser
 20 25 30
 Leu Val Phe Leu Phe Ala Met Phe Leu Phe Phe Asn His His Asp Trp
 35 40 45
 Leu Pro Gly Arg Pro Gly Phe Lys Glu Asn Pro Val Thr Tyr Thr Phe
 50 55 60
 Arg Gly Phe Arg Ser Thr Lys Ser Glu Thr Asn His Ser Ser Leu Arg
 65 70 75 80
 Thr Ile Trp Lys Glu Val Ala Pro Gln Thr Leu Arg Pro His Ile Ala
 85 90 95
 Ser Asn Ser Ser Asn Thr Glu Leu Ser Pro Gln Gly Val Thr Gly Leu
 100 105 110
 Gln Asn Thr Leu Ser Ala Asn Gly Ser Ile Tyr Asn Glu Lys Gly Thr
 115 120 125
 Gly His Pro Asn Ser Tyr His Phe Lys Tyr Ile Ile Asn Glu Pro Glu
 130 135 140
 Lys Cys Gln Glu Lys Ser Pro Phe Leu Ile Leu Ile Ala Ala Glu
 145 150 155 160
 Pro Gly Gln Ile Glu Ala Arg Arg Ala Ile Arg Gln Thr Trp Gly Asn
 165 170 175
 Glu Thr Leu Ala Pro Gly Ile Gln Ile Ile Arg Val Phe Leu Leu Gly
 180 185 190
 Ile Ser Ile Lys Leu Asn Gly Tyr Leu Gln His Ala Ile Gln Glu Glu
 195 200 205
 Ser Arg Gln Tyr His Asp Ile Ile Gln Gln Glu Tyr Leu Asp Thr Tyr
 210 215 220
 Tyr Asn Leu Thr Ile Lys Thr Leu Met Gly Met Asn Trp Val Ala Thr
 225 230 235 240
 Tyr Cys Pro His Thr Pro Tyr Val Met Lys Thr Asp Ser Asp Met Phe
 245 250 255
 Val Asn Thr Glu Tyr Leu Ile His Lys Leu Leu Lys Pro Asp Leu Pro
 260 265 270
 Pro Arg His Asn Tyr Phe Thr Gly Tyr Leu Met Arg Gly Tyr Ala Pro
 275 280 285
 Asn Arg Asn Lys Asp Ser Lys Trp Tyr Met Pro Pro Asp Leu Tyr Pro
 290 295 300
 Ser Glu Arg Tyr Pro Val Phe Cys Ser Gly Thr Gly Tyr Val Phe Ser
 305 310 315 320
 Gly Asp Leu Ala Glu Lys Ile Phe Lys Val Ser Leu Gly Ile Arg Arg

325	330	335
Leu His Leu Glu Asp Val Tyr Val Gly Ile Cys Leu Ala Lys Leu Arg		
340	345	350
Val Asp Pro Val Pro Pro Pro Asn Glu Phe Val Phe Asn His Trp Arg		
355	360	365
Val Ser Tyr Ser Ser Cys Lys Tyr Ser His Leu Ile Thr Ser His Gln		
370	375	380
Phe Gln Pro Ser Glu Leu Ile Lys Tyr Trp Asn His Leu Gln Gln Asn		
385	390	395
Lys His Asn Ala Cys Ala Asn Ala Ala Lys Glu Lys Ala Gly Arg Tyr		
405	410	415
Arg His Arg Lys Leu His		
420		

<210> 27
<211> 331
<212> PRT
<213> Mus musculus

<400> 27		
Met Ala Pro Ala Val Leu Thr Ala Leu Pro Asn Arg Met Ser Leu Arg		
1	5	10
Ser Leu Lys Trp Ser Leu Leu Leu Ser Leu Leu Ser Phe Leu Val		
20	25	30
Ile Trp Tyr Leu Ser Leu Pro His Tyr Asn Val Ile Glu Arg Val Asn		
35	40	45
Trp Met Tyr Phe Tyr Glu Tyr Glu Pro Ile Tyr Arg Gln Asp Phe Arg		
50	55	60
Phe Thr Leu Arg Glu His Ser Asn Cys Ser His Gln Asn Pro Phe Leu		
65	70	75
Val Ile Leu Val Thr Ser Arg Pro Ser Asp Val Lys Ala Arg Gln Ala		
85	90	95
Ile Arg Val Thr Trp Gly Glu Lys Ser Trp Trp Gly Tyr Glu Val		
100	105	110
Leu Thr Phe Phe Leu Leu Gly Gln Ala Glu Arg Glu Asp Lys Thr		
115	120	125
Leu Ala Leu Ser Leu Glu Asp Glu His Val Leu Tyr Gly Asp Ile Ile		
130	135	140
Arg Gln Asp Phe Leu Asp Thr Tyr Asn Asn Leu Thr Leu Lys Thr Ile		
145	150	155
Met Ala Phe Arg Trp Val Met Glu Phe Cys Pro Asn Ala Lys Tyr Ile		
165	170	175
Met Lys Thr Asp Thr Asp Val Phe Ile Asn Thr Gly Asn Leu Val Lys		
180	185	190
Tyr Leu Leu Asn Leu Asn His Ser Glu Lys Phe Phe Thr Gly Tyr Pro		
195	200	205
Leu Ile Asp Asn Tyr Ser Tyr Arg Gly Phe Phe His Lys Asn His Ile		
210	215	220
Ser Tyr Gln Glu Tyr Pro Phe Lys Val Phe Pro Pro Tyr Cys Ser Gly		
225	230	235
Leu Gly Tyr Ile Met Ser Gly Asp Leu Val Pro Arg Val Tyr Glu Met		
245	250	255
Met Ser His Val Lys Pro Ile Lys Phe Glu Asp Val Tyr Val Gly Ile		
260	265	270

Cys Leu Asn Leu Leu Lys Val Asp Ile His Ile Pro Glu Asp Thr Asn
 275 280 285
 Leu Phe Phe Leu Tyr Arg Ile His Leu Asp Val Cys Gln Leu Arg Arg
 290 295 300
 Val Ile Ala Ala His Gly Phe Ser Ser Lys Glu Ile Ile Thr Phe Trp
 305 310 315 320
 Gln Val Met Leu Arg Asn Thr Thr Cys His Tyr
 325 330

<210> 28
<211> 371
<212> PRT
<213> Mus musculus

<400> 28
 Met Pro Leu Ser Leu Phe Arg Arg Val Leu Leu Ala Val Leu Leu Leu
 1 5 10 15
 Val Ile Ile Trp Thr Leu Phe Gly Pro Ser Gly Leu Gly Glu Glu Leu
 20 25 30
 Leu Ser Leu Ser Leu Ala Ser Leu Leu Pro Ala Pro Ala Ser Pro Gly
 35 40 45
 Pro Pro Leu Ala Leu Pro Arg Leu Leu Ile Ser Asn Ser His Ala Cys
 50 55 60
 Gly Gly Ser Gly Pro Pro Pro Phe Leu Leu Ile Leu Val Cys Thr Ala
 65 70 75 80
 Pro Glu His Leu Asn Gln Arg Asn Ala Ile Arg Ala Ser Trp Gly Ala
 85 90 95
 Ile Arg Glu Ala Arg Gly Phe Arg Val Gln Thr Leu Phe Leu Leu Gly
 100 105 110
 Lys Pro Arg Arg Gln Gln Leu Ala Asp Leu Ser Ser Glu Ser Ala Ala
 115 120 125
 His Arg Asp Ile Leu Gln Ala Ser Phe Gln Asp Ser Tyr Arg Asn Leu
 130 135 140
 Thr Leu Lys Thr Leu Ser Gly Leu Asn Trp Val Asn Lys Tyr Cys Pro
 145 150 155 160
 Met Ala Arg Tyr Ile Leu Lys Thr Asp Asp Asp Val Tyr Val Asn Val
 165 170 175
 Pro Glu Leu Val Ser Glu Leu Ile Gln Arg Gly Gly Pro Ser Glu Gln
 180 185 190
 Trp Gln Lys Gly Lys Glu Ala Gln Glu Glu Thr Thr Ala Ile His Glu
 195 200 205
 Glu His Arg Gly Gln Ala Val Pro Leu Leu Tyr Leu Gly Arg Val His
 210 215 220
 Trp Arg Val Arg Pro Thr Arg Thr Pro Glu Ser Arg His His Val Ser
 225 230 235 240
 Glu Glu Leu Trp Pro Glu Asn Trp Gly Pro Phe Pro Pro Tyr Ala Ser
 245 250 255
 Gly Thr Gly Tyr Val Leu Ser Ile Ser Ala Val Gln Leu Ile Leu Lys
 260 265 270
 Val Ala Ser Arg Ala Pro Pro Leu Pro Leu Glu Asp Val Phe Val Gly
 275 280 285
 Val Ser Ala Arg Arg Gly Gly Leu Ala Pro Thr His Cys Val Lys Leu
 290 295 300
 Ala Gly Ala Thr His Tyr Pro Leu Asp Arg Cys Cys Tyr Gly Lys Phe

305	310	315	320
Leu Leu Thr Ser His Lys Val Asp Pro Trp Gln Met Gln Glu Ala Trp			
325	330	335	
Lys Leu Val Ser Gly Met Asn Gly Glu Arg Thr Ala Pro Phe Cys Ser			
340	345	350	
Trp Leu Gln Gly Phe Leu Gly Thr Leu Arg Cys Arg Phe Ile Ala Trp			
355	360	365	
Phe Ser Ser			
370			

<210> 29
<211> 325
<212> PRT
<213> Mus musculus

<400> 29

Met Lys Val Phe Arg Arg Ala Trp Arg His Arg Val Ala Leu Gly Leu			
1	5	10	15
Gly Gly Leu Ala Phe Cys Gly Thr Thr Leu Leu Tyr Leu Ala Arg Cys			
20	25	30	
Ala Ser Glu Gly Glu Thr Pro Ser Ala Ser Gly Ala Ala Arg Pro Arg			
35	40	45	
Ala Lys Ala Phe Leu Ala Val Leu Val Ala Ser Ala Pro Arg Ala Val			
50	55	60	
Glu Arg Arg Thr Ala Val Arg Ser Thr Trp Leu Ala Pro Glu Arg Arg			
65	70	75	80
Gly Gly Pro Glu Asp Val Trp Ala Arg Phe Ala Val Gly Thr Gly Gly			
85	90	95	
Leu Gly Ser Glu Glu Arg Arg Ala Leu Glu Leu Glu Gln Ala Gln His			
100	105	110	
Gly Asp Leu Leu Leu Pro Ala Leu Arg Asp Ala Tyr Glu Asn Leu			
115	120	125	
Thr Ala Lys Val Leu Ala Met Leu Thr Trp Val Asp Glu Arg Val Asp			
130	135	140	
Phe Glu Phe Val Ile Lys Ala Asp Asp Asp Ser Phe Ala Arg Leu Asp			
145	150	155	160
Ala Ile Leu Val Asp Leu Arg Ala Arg Glu Pro Ala Arg Arg Arg Arg			
165	170	175	
Leu Tyr Trp Gly Phe Phe Ser Gly Arg Gly Arg Val Lys Pro Gly Gly			
180	185	190	
Arg Trp Arg Glu Ala Ala Trp Gln Leu Cys Asp Tyr Tyr Leu Pro Tyr			
195	200	205	
Ala Leu Gly Gly Tyr Val Leu Ser Ala Asp Leu Val His Tyr Ile			
210	215	220	
Arg Leu Ser Arg Glu Tyr Leu Arg Ala Trp His Ser Glu Asp Val Ser			
225	230	235	240
Leu Gly Thr Trp Leu Ala Pro Val Asp Val Gln Arg Glu His Asp Pro			
245	250	255	
Arg Phe Asp Thr Glu Tyr Lys Ser Arg Gly Cys Asn Asn Gln Tyr Leu			
260	265	270	
Val Thr His Lys Gln Ser Pro Glu Asp Met Leu Glu Lys Gln Gln Met			
275	280	285	
Leu Leu His Glu Gly Arg Leu Cys Lys His Glu Val Gln Leu Arg Leu			
290	295	300	

WO 01/85177

PCT/US01/15452

Ser Tyr Val Tyr Asp Trp Ser Ala Pro Pro Ser Gln Cys Cys Gln Arg
305 310 315 320
Lys Glu Gly Val Pro
325

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/15452

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/70, 48/00; C07H 21/04; C12N 9/10
 US CL : 424/279.1; 514/23, 44; 536/23.2; 435/183, 193

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 424/279.1; 514/23, 44; 536/23.2; 435/183, 193

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/49018 A1 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 30 September 1999 (30.09.1999), see entire document.	1-29
Y	BISTRUP ET AL. Sulfotransferases of Two Specificities Function in the Reconstitution of High Endothelial Cell Ligands for L-selectin. J. Cell Biol. 17 May 1999, Vol 145, No. 4, pages 899-910, see entire document.	1-29
Y	LEB ET AL. Cloning and Characterization of a Mammalian N-Acetylglucosamine-6-sulfotransferase That Is Highly Restricted to Intestinal Tissue. Biochem. Biophys. Res. Com. 1999, Vol. 263, pages 543-549, see entire document.	1-29
Y	HIRAOKA ET AL. A Novel, High Endothelial Venule-Specific Sulfotransferase Expresses 6-Sulfo Sialyl LewisX, an L-Selectin Ligand Displayed by CD34. Immunity. July 1999, Vol 11, pages 79-89, see entire document.	1-29
Y	KIMURA ET AL. Reconstitution of functional L-selectin ligands on a cultured human endothelial cell line by cotransfection of alpha 1->3 fucosyltransferase VII and newly cloned GlcNAcbeta:6-sulfotransferase cDNA. Proc. Natl. Acad. Sci. USA. April 1999, Vol. 96, pages 4530-4535, see entire document.	1-29

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
* Special categories of cited documents:			
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"A"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	27 June 2001 (27.06.2001)	Date of mailing of the international search report	26 JUL 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Jessica H. Roark Telephone No. (703) 308-0196	<i>Nelal Collins for</i>	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/15452

Continuation of B. FIELDS SEARCHED Item 3: WEST, MEDLINE, CAPLUS, GENBANK® search terms: inventor names, MECA-79, sulfotransferase, L-selectin